(51) International Patent Classification⁷: **A61K 38/54**

(21) International Application Number:
PCT/US2005/016920

(22) International Filing Date: 13 May 2005 (13.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/571,648   13 May 2004 (13.05.2004)   US

(71) Applicant *(for all designated States except US)*: **IM-CLONE SYSTEMS INCORPORATED** [US/US]; 180 Varick Street, New York, NY 10014 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: **PEREIRA, Daniel** [CA/US]; 11 Bolten Place, Bloomfield, NJ 07003 (US).

(74) Agents: **SOMERVILLE, Deborah, A.** et al.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHIBITION OF MACROPHAGE-STIMULATING PROTEIN RECEPTOR (RON)

(57) Abstract: The present invention relates to methods for treatment of tumors and other diseases in a mammal comprising administration of antibodies specific for Macrophage-Stimulating Protein Receptor ("MSP-R" or "RON"). The present invention further provides for compositions comprising antibodies of antibody fragments specific for Ron, including human antibodies, that inhibit RON activation.

INHIBITION OF MACROPHAGE-STIMULATING PROTEIN RECEPTOR (RON)

FIELD OF THE INVENTION

[01]   The present invention relates to methods for treatment of tumors and other diseases in a mammal comprising administration of antibodies specific for Macrophage-Stimulating Protein Receptor ("MSP-R" or "RON"). The present invention further provides for compositions comprising antibodies or antibody fragments specific for RON, including human antibodies, that inhibit RON activation.

BACKGROUND OF THE INVENTION

[02]   RON belongs to the c-met family of receptor tyrosine kinases. RON is a heterodimeric protein comprised of an extracellular alpha chain and a transmembrane beta chain. RON is first expressed as a single chain precursor, followed by cleavage into the alpha and the beta chains (1). It is believed that the beta chain is required for binding of MSP to the receptor, and Kringle domains of 2 and 3 are required for RON/MSP interaction. U.S. Publ. No. 2003/0073656. The extracelllular domain of RON is thought to have little homology with the corresponding domains of the c-met family receptors. Indeed, binding of Hepatocyte Growth Factor (HGF), which stimulates other receptors in the c-met family, to the RON receptor, does not stimulate tyrosine kinase activity. WO02/083047.

[03]   RON is thought to have a role in cell migration, shape change and invasion (1). An earlier publication however found limited role for RON for inducing transformation, but found promotion of invasive growth by RON activation (16). U.S. Publ. No. 2003/0073656 speculates that activation of RON may play a role in diseases to the liver, biliary tract, bile ducts, gall bladder and related hepatobiliary system.

[04]   Mutations, deletions, gene rearrangements and alternative mRNA splicing may cause activation of RON without any ligand binding (1). Variations in the tyrosine kinase domain of RON may play an important role in activation of RON (1). Cloning of RON from various cancer cell lines, has shown RON activation due to various defects in the mRNA encoding for RON.

[05]   In addition to c-met's ligand (HGF), the ligand for RON (Macrophage-Stimulating Protein; MSP aka. HGF-like protein) is a member of the kringle-domain plasminogen-related protein family (1). As its name implies, MSP was originally found to stimulate macrophages by a variety of means (2,3). For example, addition of MSP to certain RON-expressing macrophages induced shape changes, chemotaxis, macropinocytosis, phagocytosis and immune mediator production (4, 5, 6). RON was also found to be expressed in epithelial cells such as keratinocytes where MSP was shown to phosphorylate RON and activate a number of signaling pathways that elicited cell adhesion/motility, anti-apoptotic and proliferative responses (7,8). Within the last few years, over-expression of RON has been observed in several epithelial tumors and cell lines (ex. colon (9, 10, 11), lung (12), breast (13)). In a recent study, lung tumors developed in transgenic mice engineered to over-express RON in their lungs (14,15).

[06]   Studies to address whether inhibition of RON could abrogate tumor or cancer cell line growth have not been reported.

SUMMARY OF THE INVENTION

[07]   The present invention relates to methods for treatment of tumors and other diseases in a mammal comprising administration of antibodies specific for Macrophage-Stimulating Protein Receptor ("MSP-R" or "RON"). The present invention further provides for compositions comprising antibodies or antibody fragments specific for RON, including human antibodies, that inhibit RON activation.

[08]   The present invention further provides a monoclonal antibody, or fragment thereof, specific for RON comprising one or more heavy chain CDR sequences selected from the group consisting of SEQ ID NO: 2 (SYAMH) for CDR1; SEQ ID NO: 4 (VISYDGSNKYYADSVKG) for CDR2 and SEQ ID NO: 6 for CDR3 (FSGWPNNYYYYGMDV).

[09]   The present invention further provides a monoclonal antibody, or a fragment thereof, specific for RON comprising one or more light chain CDR sequences selected

from the group consisting of SEQ ID NO: 11 for CDR1 (RSSQSLLHSNGFNYVD); SEQ ID NO: for CDR2 (FGSYRAS) and SEQ ID NO: 15 for CDR3 (MQALQTPPWT).

[10]   The present invention further provides a monoclonal antibody, or a fragment thereof, specific for RON comprising one or more light chain CDR sequences selected from the group consisting of SEQ ID NO: 50 for CDR1 (RSSQSLLHSNGYNYLD); SEQ ID NO: 52 for CDR2 (LGSNRAS) and SEQ ID NO: for CDR3 (MQALQTPRT).

[11]   The present invention further provides a monoclonal antibody, or fragment thereof, specific for RON comprising one or more heavy chain CDR sequences selected from the group consisting of SEQ ID NO: 20 (SHYWS) for CDR1; SEQ ID NO: 23 · (YIYYSGSTNYNPSLKS) for CDR2 and SEQ ID NO: for CDR3 (IPNYYDRSGYYPGYWYFDL).

[12]   The present invention further provides a monoclonal antibody, or fragment thereof, specific for RON comprising one or more light chain CDR sequences selected from the group consisting of SEQ ID NO: for CDR1 (TLRSGFNVDSYRIS); SEQ ID NO: for CDR2 (YKSDSDK) and SEQ ID NO: 18 for CDR3 (MIWHSSAWV).

[13]   The present invention further provides isolated nucleic acids encoding RON specific antibodies and antibody fragments. Also provided are expression vectors, host cells comprising the expression vectors and methods for producing RON specific antibodies comprising culturing a host cell.

[14]   The present invention further provides a pharmaceutical compositions comprising RON specific monoclonal antibodies, or fragment thereof. Such compositions may be used in methods for inhibiting growth of mammalian tumor cells that express RON comprising administering an effective amount of an antibody or a fragment thereof specific for RON. The present invention further provides a method for inhibiting metastatic activity of mammalian tumor cells that express RON, comprising administering an effective amount of an antibody or a fragment thereof specific for RON. The present invention provides a method for treating inflammation mediated by RON activity in a

mammal comprising administering to the mammal an antibody or an antibody fragment specific for RON.

[15]   In addition to administration of RON specific antibodies, the methods of the present invention further provide for administering a small organic molecule, wherein the small organic molecule is a chemotherapeutic agent, anti-angiogenesis agent or inhibits activation of RON.

[16]   In addition to administration of RON specific antibodies, the methods of the present invention further provide for administering one or more antibodies specific to a receptor tyrosine kinase, such as EGFR or VEGFR.

[17]   The present invention provides a therapeutic composition for inhibition of growth of tumor cells that express RON in a mammal comprising an antibody, or fragment thereof, specific for RON.

[18]   The present invention further provides a method for detecting presence of RON comprising contacting RON with the above antibody pr a fragment thereof.

BRIEF DESCRIPTION OF THE FIGURES

[19]   Figure 1 provides a chart plotting size of tumors against time in mice after administration of IMC-41A10.

[20]   Figure 2 defines various SEQ ID Nos. including those of the antibodies of the present invention.

[21]   Figure 3 is a western blot illustrating inhibition of MSP induced phosphorylation by IMC-41A10.

DETAILED DESCRIPTION OF THE INVENTION

[22]   The present invention provides a method of inhibiting growth, proliferation, metastatic activity (i.e. migration and/or invasion) of tumor cells that express RON by administration of an effective amount of an antibody or a fragment thereof that inhibits activation of RON. The invention also provides therapeutic compositions of an antibody, or fragment thereof, specific for RON. Further, the present invention provides fully

human antibodies to the human RON receptor tyrosine kinase. Such antibodies include but are not limited to IMC-41A2, IMC-41A10 and IMC-41B12, and fragments thereof.

[23]   Naturally occurring antibodies typically have two identical heavy chains and two identical light chains, with each light chain covalently linked to a heavy chain by an inter-chain disulfide bond and multiple disulfide bonds further link the two heavy chains to one another. Individual chains can fold into domains having similar sizes (110-125 amino acids) and structures, but different functions. The light chain can comprise one variable domain (V_L) and/or one constant domain (C_L). The heavy chain can also comprise one variable domain (V_H) and/or, depending on the class or isotype of antibody, three or four constant domains (C_H1, C_H2, C_H3 and C_H4). In humans, the isotypes are IgA, IgD, IgE, IgG, and IgM, with IgA and IgG further subdivided into subclasses or subtypes (IgA_{1-2} and IgG_{1-4}).

[24]   Generally, the variable domains show considerable amino acid sequence variability from one antibody to the next, particularly at the location of the antigen-binding site. Three regions, called hypervariable or complementarity-determining regions (CDRs), are found in each of V_L and V_H, which are supported by less variable regions called framework variable regions.

[25]   The portion of an antibody consisting of V_L and V_H domains is designated Fv (Fragment variable) and constitutes the antigen-binding site. Single chain Fv (scFv) is an antibody fragment containing a V_L domain and a V_H domain on one polypeptide chain, wherein the N terminus of one domain and the C terminus of the other domain are joined by a flexible linker (see, e.g., U.S. Pat. No. 4,946,778 (Ladner et al.); WO 88/09344, (Huston et al.). WO 92/01047 (McCafferty et al.) describes the display of scFv fragments on the surface of soluble recombinant genetic display packages, such as bacteriophage.

[26]   The peptide linkers used to produce the single chain antibodies can be flexible peptides selected to assure that the proper three-dimensional folding of the V_L and V_H

domains occurs. The linker is generally 10 to 50 amino acid residues. Preferably, the

linker is 10 to 30 amino acid residues. More preferably the linker is 12 to 30 amino acid

residues. Most preferably is a linker of 15 to 25 amino acid residues. An example of such

linker peptides includes repeats of four Glycines followed by Serine.

[27]   Single chain antibodies lack some or all of the constant domains of the whole

antibodies from which they are derived. Therefore, they can overcome some of the

problems associated with the use of whole antibodies. For example, single-chain

antibodies tend to be free of certain undesired interactions between heavy-chain constant

regions and other biological molecules. Additionally, single-chain antibodies are

considerably smaller than whole antibodies and can have greater permeability than whole

antibodies, allowing single-chain antibodies to localize and bind to target antigen-binding

sites more efficiently. Furthermore, the relatively small size of single-chain antibodies

makes them less likely to provoke an unwanted immune response in a recipient than whole

antibodies.

[28]   Multiple single chain antibodies, each single chain having one V_H and one V_L

domain covalently linked by a first peptide linker, can be covalently linked by at least one

or more peptide linker to form a multivalent single chain antibodies, which can be

monospecific or multispecific. Each chain of a multivalent single chain antibody includes

a variable light chain fragment and a variable heavy chain fragment, and is linked by a

peptide linker to at least one other chain. The peptide linker is composed of at least fifteen

amino acid residues. The maximum number of amino acid residues is about one hundred.

[29]   Two single chain antibodies can be combined to form a diabody, also known as

a bivalent dimer. Diabodies have two chains and two binding sites, and can be

monospecific or bispecific. Each chain of the diabody includes a V_H domain connected to

a V_L domain. The domains are connected with linkers that are short enough to prevent

pairing between domains on the same chain, thus driving the pairing between complementary domains on different chains to recreate the two antigen-binding sites.

[30]   Three single chain antibodies can be combined to form triabodies, also known as trivalent trimers. Triabodies are constructed with the amino acid terminus of a V_L or V_H domain directly fused to the carboxyl terminus of a V_L or V_H domain, i.e., without any linker sequence. The triabody has three Fv heads with the polypeptides arranged in a cyclic, head-to-tail fashion. A possible conformation of the triabody is planar with the three binding sites located in a plane at an angle of 120 degrees from one another. Triabodies can be monospecific, bispecific or trispecific.

[31]   Fab (Fragment, antigen binding) refers to the fragments of the antibody consisting of V_L C_L V_H C_{H1} domains. Those generated following papain digestion simply are referred to as Fab and do not retain the heavy chain hinge region. Following pepsin digestion, various Fabs retaining the heavy chain hinge are generated. Those fragments with the interchain disulfide bonds intact are referred to as $F(ab')_2$, while a single Fab' results when the disulfide bonds are not retained. $F(ab')_2$ fragments have higher avidity for antigen that the monovalent Fab fragments.

[32]   Fc (Fragment crystallization) is the designation for the portion or fragment of an antibody that comprises paired heavy chain constant domains. In an IgG antibody, for example, the Fc comprises C_{H2} and C_{H3} domains. The Fc of an IgA or an IgM antibody further comprises a C_{H4} domain. The Fc is associated with Fc receptor binding, activation of complement-mediated cytotoxicity and antibody-dependent cellular-cytotoxicity (ADCC). For antibodies such as IgA and IgM, which are complexes of multiple IgG like proteins, complex formation requires Fc constant domains.

[33]   Finally, the hinge region separates the Fab and Fc portions of the antibody, providing for mobility of Fabs relative to each other and relative to Fc, as well as including multiple disulfide bonds for covalent linkage of the two heavy chains.

[34]   Thus, antibodies specific to RON include, but are not limited to, naturally occurring antibodies, bivalent fragments such as (Fab')$_2$, monovalent fragments such as Fab, single chain antibodies, single chain Fv (scFv), single domain antibodies, multivalent single chain antibodies, diabodies, triabodies, and the like that bind specifically with antigens.

[35]   Each domain of the antibodies of this invention can be a complete antibody with the heavy or light chain variable domain, or it can be functionally the same or a mutant or derivative of a naturally-occurring domain, or a synthetic domain constructed, for example, *in vitro* using a technique such as one described in WO 93/11236 (Griffiths et al.). For instance, it is possible to join together domains corresponding to antibody variable domains, which are missing at least one amino acid. The important characterizing feature is the ability of each domain to associate with a complementary domain to form an antigen-binding site. Accordingly, the terms variable heavy and light chain fragment should not be construed to exclude variants that do not have a material effect on specificity.

[36]   As used herein, "antibodies" and "antibody fragments" includes modifications that retain specificity for the RON receptor. Such modifications include, but are not limited to, conjugation to an effector molecule such as a chemotherapeutic agent (*e.g.*, cisplatin, taxol, doxorubicin) or cytotoxin (*e.g.*, a protein, or a non-protein organic chemotherapeutic agent). The antibodies can be modified by conjugation to detectable reporter moieties. Also included are antibodies with alterations that affect non-binding characteristics such as half-life (*e.g.*, pegylation).

[37]   Proteins and non-protein agents may be conjugated to the antibodies by methods that are known in the art. Conjugation methods include direct linkage, linkage via covalently attached linkers, and specific binding pair members (*e.g.*, avidin-biotin). Such methods include, for example, that described by Greenfield et al., Cancer Research

50, 6600-6607 (1990) for the conjugation of doxorubicin and those described by Arnon et al., Adv. Exp. Med. Biol. 303, 79-90 (1991) and by Kiseleva et al., Mol. Biol. (USSR)25, 508-514 (1991) for the conjugation of platinum compounds.

[38]   Antibody specificity refers to selective recognition of the antibody for a particular epitope of an antigen. Antibodies, or fragments thereof, of the present invention, for example, can be monospecific or bispecific. Bispecific antibodies (BsAbs) are antibodies that have two different antigen-binding specificities or sites. Where an antibody has more than one specificity, the recognized epitopes can be associated with a single antigen or with more than one antigen. Thus, the present invention provides bispecific antibodies, or fragments thereof, that bind to two different antigens, with at least one specificity for RON.

[39]   Specificity of antibodies, or fragments thereof, for RON can be determined based on affinity and/or avidity. Affinity, represented by the equilibrium constant for the dissociation of an antigen with an antibody (K_d), measures the binding strength between an antigenic determinant and an antibody-binding site. Avidity is the measure of the strength of binding between an antibody with its antigen. Avidity is related to both the affinity between an epitope with its antigen binding site on the antibody, and the valence of the antibody, which refers to the number of antigen binding sites of a particular epitope. Antibodies typically bind with a dissociation constant (K_d) of about 10^{-5} to about 10^{-11} liters/mol (e.g., K_D <100 nM). Any K_d less than about 10^{-4} liters/mol is generally considered to indicate nonspecific binding. The lesser the value of the K_d, the stronger the binding strength between an antigenic determinant and the antibody binding site.

[40]   RON may be isolated from various sources to raise an immune response, such as from cells that express RON: colon, pancreatic, prostate, stomach, lung, liver, ovarian, kidney, breast and brain, and in general epithelial and neuroendocrine. Also, a synthetic receptor peptide may be obtained using commercially available machines and the corresponding amino acid sequence. A further alternative still, is that DNA encoding a

RON such as a cDNA or a fragment thereof, may be cloned and expressed and the resulting polypeptide recovered and used as an immunogen to raise an antibody of the invention. In order to prepare RON against which the antibodies are made, nucleic acid molecules that encode RON, or portions thereof, especially the extracellular portions thereof (particularly alpha and beta portion), may be inserted into known vectors for expression in host cells using standard recombinant DNA techniques. Similarly, antibodies against ligands of RON, particularly MSP, may be prepared.

[41]   The sequences for RON and its ligand MSP are publicly available and can readily be used for antibody preparation. Antibodies may also be produced against variants/mutants of RON or MSP. Of interest are antibodies to epitopes present on extracellular domains of variants and mutants. An altered RON receptor differing by an in-frame deletion of 109 amino acids in the extracellular domain has been shown to be constitutively activated (1). Antibodies may for example be generated against such altered RON receptor.

[42]   Antibodies specific to RON may be prepared by immunizing a mammal with RON. The soluble receptors may be used by themselves as immunogens, or attached to a carrier protein or other objects, such as beads, i.e. sepharose beads. After the mammal has produced antibodies, a mixture of antibody producing cells, such as splenocytes, are isolated. Monoclonal antibodies may be produced by isolating individual antibody-producing cells from the mixture and immortalizing them by, for example, fusing them with tumor cells, such as myeloma cells. The resulting hybridomas are preserved in culture, and express monoclonal antibodies, which are harvested from the culture medium.

[43]   Further, antibodies and antibody fragments of the invention can be obtained by standard hybridoma technology (Harlow & Lane, ed., Antibodies: A Laboratory Manual, Cold Spring Harbor, 211-213 (1998), which is incorporated by reference herein) using transgenic mice (e.g., KM mice from Medarex, San Jose, Calif.) that produce human immunoglobulin heavy and light chains. In a preferred embodiment, a substantial portion of the human antibody producing genome is inserted into the genome of the mouse, and is

rendered deficient in the production of endogenous murine antibodies. Such mice may be immunized subcutaneously (s.c.) with RON in complete Freund's adjuvant. The antibodies of this invention can be fused to additional amino acid residues. Such amino acid residues can be a peptide tag, perhaps to facilitate isolation. Other amino acid residues for homing of the antibodies to specific organs or tissues are also contemplated.

[44]   Anti-RON antibodies according to the present invention can be isolated from a phage display library such as one constructed from human heavy chain and light chain variable region genes. For example, a variable domain of the invention can be obtained from peripheral blood lymphocytes that contains a rearranged variable region gene. Alternatively, variable domain portions, such as CDR and FW regions, can be obtained from different human sequences.

[45]   The antibodies specific to RON bind to RON with a K_d of preferably about $1 \times 10^{-9} \, M^{-1}$ or less, more preferably about $1 \times 10^{-10} \, M^{-1}$ or less, and most preferably about $1 \times 10^{-11} \, M^{-1}$ or less.

[46]   Antibodies, or fragments thereof, specific for RON, inhibit activation of the receptor. Inhibiting a receptor means preventing the activation of the intrinsic kinase activity of the receptor to transduce a signal. A reliable assay for RON is the inhibition of receptor phosphorylation.

[47]   The present invention is not limited by any particular mechanism of RON inhibition. Such inhibition for example may occur by an antibody blocking access to certain epitopes by a ligand, or by changing conformation of RON in a manner that the ligand, particularly MSP, can not activate the receptor even though it can bind to the receptor. USP 6,165,464 lists various possible mechanisms for such inhibition, including binding to the ligand itself, down regulating the receptor, inhibiting the tyrosine kinase activity of the receptor, or illiciting a cytotoxic response. Down regulation may occur when cells that express RON, particularly those that overexpress (including differentially express) RON, decrease the number of RON receptor tyrosine kinases on their surface. Matrix metalloproteinases, which function in tumor cell invasion and metastasis, may also be down regulated by the antibodies of the present invention.

[48]   RON inhibition has various effects, including inhibition, diminution, inactivation and/or disruption of growth (proliferation and differentiation), angiogenesis (blood vessel recruitment, invasion, and metastasis), and cell motility and metastasis (cell adhesion and invasiveness).

[49]   The invention also contemplates antibodies that bind to and inactivate variant or mutated RON receptor tyrosine kinases that are active without ligand binding. A mammal suffering from a RON related disease may for example express both wild type and variant RON, with a disproportionate amount of the variant receptor. Of interest are sequences of variants/mutants differing in the extracellular domain, such as those having deletions within the extracellular domain, as disclosed by Wang (1) (9). Thus RON inhibition may involve wild type and/or variant RON (point mutations, deletions, alternative splicing, etc.).

[50]   RON activation may occur through dimerization and activation with other RTKs such as c-met or EGFR. Thus, RON inhibition may also include inhibition of heterodimerization between RON and other RTKs such as EGFR or c-met. Such inhibition may also include inhibition of signaling by a formed heterodimer of RON and EGF or c-met as an example. Such dimerization may have been induced   in a lignad dependent fashion, such as by MSP, HGF or EGF binding to their receptors and inducing dimerization.

[51]   One measure of RON inhibition is inhibition of the tyrosine kinase activity of the receptor. Tyrosine kinase inhibition can be determined using well-known methods; for example, by measuring the autophosphorylation level of recombinant kinase receptor, and/or phosphorylation of natural or synthetic substrates. Thus, phosphorylation assays are useful in determining inhibiting antibodies in the context of the present invention. Phosphorylation can be detected, for example, using an antibody specific for phosphotyrosine in an ELISA assay or on a western blot. Some assays for tyrosine kinase activity are described in Panek et al., *J. Pharmacol. Exp. Thera.* 283: 1433-44 (1997) and Batley et al., *Life Sci.* 62:143-50 (1998).

[52]   In addition, methods for detection of protein expression can be utilized to determine RON inhibition. These methods include immunohistochemistry (IHC) for detection of protein expression, fluorescence *in situ* hybridization (FISH) for detection of gene amplification, competitive radioligand binding assays, solid matrix blotting techniques, such as Northern and Southern blots, reverse transcriptase polymerase chain reaction (RT-PCR) and ELISA.

[53]   Another measure of RON inhibition of phosphorylation of downstream substrates of RON. Accordingly, the level of phosphorylation of MAPK or Akt can be measured.

[54]   In a preferred embodiment, an antibody specific to RON having one, two, three, four, five, or all six complementarity-determining regions (CDRs) of the antibodies of the present invention is administered to a mammal. In one embodiment, the antibody administered has the variable regions of the antibodies of the present invention. Figure 2 provides a summary of the sequences of the antibodies of the present invention. It is believed that IMC-41A2, IMC-41A10 and IMC-41B12 bind to the beta extracellular domain of RON, but such specificity may also arise by binding to other domains of RON, or binding to different epitopes in the same domain.

[55]   CDRs of antibodies isolated according to the present invention include:
Heavy Chain (IMC-41A2)...............................

CDR1H	SYAMH
CDR2H	VISYDGSNKYYADSVKG
CDR3H	FSGWPNNYYYYGMDV

Light Chain (IMC-41A2)

CDR1L	RSSQSLLHSNGYNYLD
CDR2L	LGSNRAS
CDR3L	·MQALQTPRT

Heavy Chain (IMC-41A10)

CDR1	SYAMH
CDR2	VISYDGSNKYYADSVKG
CDR3	FSGWPNNYYYYGMDV

Light Chain (IMC-41A10)
CDR1   RSSQSLLHSNGFNYVD
CDR2   FGSYRAS
CDR3   MQALQTPPWT
Heavy Chain (IMC-41B12)
CDR1   SHYWS
CDR2   YIYYSGSTNYNPSLKS
CDR3   IPNYYDRSGYYPGYWYFDL
Light Chain (IMC-41B12)
CDR1   TLRSGFNVDSYRIS
CDR2   YKSDSDK
CDR3   MIWHSSAWV

[56]   Variants of antibody and antibody fragments specific to RON also include polypeptides with amino acid sequences substantially similar to the amino acid sequence of the variable or hypervariable regions of the antibodies of the present invention. Substantially the same amino acid sequence is defined herein as a sequence with at least 70%, preferably at least about 80%, and more preferably at least about 90% homology to a compared amino acid sequence, as determined by the FASTA search method in accordance with Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85, 2444-2448 (1988), including sequences that are at least about 70%, preferably at least about 80%, and more preferably at least about 90% identical. Such antibodies will have the same or similar binding, ligand blocking, and receptor inhibiting activities to antibodies of the invention that have substantially the same CDRs.

[57]   Variants of antibody and antibody fragments specific to RON also include antibodies having one or more conservative amino acid substitutions. A conservative amino acid substitution is defined as a change in the amino acid composition by way of changing one, two or more amino acids of a peptide, polypeptide or protein, or fragment thereof. The substitution is of amino acids with generally similar properties (e.g., acidic, basic, aromatic, size, positively or negatively charged, polarity, non-polarity) such that the

substitutions do not substantially alter peptide, polypeptide or protein characteristics (e.g.,
charge, isoelectric point, affinity, avidity, conformation, solubility) or activity. Typical
substitutions that may be performed for such conservative amino acid substitution may be
among the groups of amino acids as follows:

> glycine (G), alanine (A), valine (V), leucine (L) and isoleucine (I);
>
> aspartic acid (D) and glutamic acid (E);
>
> alanine (A), serine (S) and threonine (T);
>
> histidine (H), lysine (K) and arginine (R):
>
> asparagine (N) and glutamine (Q);
>
> phenylalanine (F), tyrosine (Y) and tryptophan (W)

[58]   Conservative amino acid substitutions can be made in, e.g., regions flanking
the hypervariable regions primarily responsible for the selective and/or specific binding
characteristics of the molecule, as well as other parts of the molecule, e.g., variable heavy
chain cassette.

[59]   Antibodies, or fragments thereof, also include those for which binding
characteristics have been improved by direct mutation, methods of affinity maturation,
phage display, or chain shuffling.

[60]   Affinity and specificity can be modified or improved by mutating CDR and/or
FW residues and screening for antigen binding sites having the desired characteristics (see,
e.g., Yang et al., J. Mol. Biol., (1995) 254: 392-403). One way is to randomize individual
residues or combinations of residues so that in a population of, otherwise identical antigen
binding sites, subsets of from two to twenty amino acids are found at particular positions.
Alternatively, mutations can be induced over a range of residues by error prone PCR
methods (see, e.g., Hawkins et al., J. Mol. Biol., (1992) 226: 889-96). In another example,
phage display vectors containing heavy and light chain variable region genes can be
propagated in mutator strains of E. coli (see, e.g., Low et al., J. Mol. Biol., (1996) 250:
359-68). These methods of mutagenesis are illustrative of the many methods known to
one of skill in the art.

[61]   Another manner for increasing affinity of the antibodies of the present invention is to carry out chain shuffling, where the heavy or light chain are randomly paired with other heavy or light chains to prepare an antibody with higher affinity. The various CDRs of the antibodies may also be shuffled with the corresponding CDRs in other antibodies.

[62]   The present invention further provides for antibodies which binds specifically to the same RON epitope(s) as those bound by the IMC-14A2, IMC-14A10 and IMC-14B12 antibodies. Such antibodies may be identified by their ability to compete with IMC-14A2, IMC-14A10 and IMC-14B12 RON binding. These epitopes are present on the extracellular domain of RON.

[63]   Additionally, the present invention provides isolated polynucleotides encoding the present antibodies or fragments thereof as well as expression vectors comprising these polynucleotide sequences operably linked to an expression sequence. These nucleotides are listed in figure 2. Recombinant host cells comprising the expression vector which express the present antibodies or fragments thereof are also provided. Methods are also provided for producing antibodies or fragments thereof comprising culturing these cells under conditions permitting expression of the antibodies or fragments thereof. The antibodies or fragments thereof can then be purified from the cell or cell culture medium.

[64]   Variants of nucleotides listed in figure 2 include those that encode for an antibody or antibody fragment having the same function as the antibodies of the present invention, *i.e.*, to blocking activation of RON. Such variants have a sequence that is at least about 70%, preferably at least about 80%, and more preferably at least about 90% identical.

[65]   The present invention also provides for antibody fusion proteins. These fusion proteins may be encoded by the nucleotide sequences of figure 2 cloned adjacent to nucleotide sequences encoding enzymes, florescent proteins, a polypeptide tag or luminescent marker.

[66]   The nucleotide sequences of the invention also include: (a) the antibody DNA

sequences shown in Figure 2; (b) any nucleotide sequence that (i) hybridizes to the

nucleotide sequence set forth in (a) under stringent conditions, e.g., hybridization to filter-

bound DNA in 0.5 M NaHPO$_4$, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C,

and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel F.M. et al., eds., 1989, Current

Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley

& sons, Inc., New York, at p. 2.10.3) and (ii) encodes antibody or antibody fragment

having substantially the same functionality; and (c) any nucleotide sequence that

hybridizes to a DNA sequence that encodes the antibody sequences shown in Figure 2

under less stringent conditions, such as moderately stringent conditions, e.g., washing in

0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989 supra), yet which still encodes an

antibody or antibody fragment having substantially the same functionality. The

functionality of the antibodies of the present invention is to block activation of RON.

[67]   The present invention also provides an expression vector containing a nucleic

acid encoding an antibody of the present invention, or fragment thereof, operably linked to

a control sequence, as well as a host cell containing such an expression vector. These host

cells can be cultured under specific conditions permitting expression of antibodies of the

present invention, or fragments thereof, and the antibodies then can be purified from the

host cells.

[68]   Standard recombinant techniques and known expression vectors are used to

express the antibodies of the invention. Vectors for expressing proteins in bacteria,

especially E. Coli, are known. Such vectors include the PATH vectors described by

Dieckmann and Tza goloff in J. Biol. Chem. 260, 1513-1520 (1985). These vectors

contain DNA sequences that encode anthranilate synthetase (TrpE) followed by a

polylinker at the carboxy terminus. Other expression vector systems are based on beta-

galactosidase (pEX); lambda P$_L$; maltose binding protein (pMAL); and glutathione S-

transferase (pGST)-see Gene 67, 31 (1988) and Peptide Research 3, 167 (1990).

[69]   Vectors useful in yeast are available. A suitable example is the 2☐ plasmid. Suitable vectors for expression in mammalian cells are also known. Such vectors include well-known derivatives of SV-40, adenovirus, retrovirus-derived DNA sequences and shuttle vectors derived from combination of functional mammalian vectors, such as those described above, and functional plasmids and phage DNA.

[70]   Further eukaryotic expression vectors are known in the art (e.g., P. J. Southern and P. Berg, J. Mol. Appl. Genet. 1, 327-341 (1982); S. Subramani et al, Mol. Cell. Biol. 1, 854-864 (1981); R. J. Kaufmann and P. A. Sharp, "Amplification And Expression Of Sequences Cotransfected with A Modular Dihydrofolate Reductase Complementary DNA Gene," J. Mol. Biol. 159, 601-621 (1982); R. J. Kaufmann and P.A. Sharp, "Amplification And Expression Of Sequences Cotransfected with A Modular Dihydrofolate Reductase Complementary DNA Gene," J. Mol. Biol. 159, 601-664 (1982); S. I. Scahill et al, "Expression And Characterization Of the Product Of A Human Immune Interferon DNA Gene In Chinese Hamster Ovary Cells," Proc. Natl. Acad. Sci. USA 80, 4654-4659 (1983); G. Urlaub and L. A. Chasin, Proc. Natl. Acad. Sci. USA 77, 4216-4220, (1980)).

[71]   The expression vectors useful in the present invention contain at least one expression control sequence that is operatively linked to the DNA sequence or fragment to be expressed. The control sequence is inserted in the vector in order to control and to regulate the expression of the cloned DNA sequence. Examples of useful expression control sequences are the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of fd coat protein, the glycolytic promoters of yeast, e.g., the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, e.g., Pho5, the promoters of the yeast alphamating factors, and promoters derived from polyoma, adenovirus, retrovirus, and simian virus, e.g., the early and late promoters or SV40, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells and their viruses or combination thereof.

[72]   Vectors containing the control signals and DNA to be expressed, such as that encoding antibodies of the invention, antibody fragments thereof, are inserted into a host cell for expression. Some useful expression host cells include well-known prokaryotic and eukaryotic cells. Some suitable prokaryotic hosts include, for example, E. coli, such as E. coli SG-936, E. coli HB 101, E. coli W3110, E. coli X1776, E. coli X2282, E. coli DHI, and E. coli MRC1, Pseudomonas, Bacillus, such as Bacillus subtilis, and Streptomyces. Suitable eukaryotic cells include yeast and other fungi, insect, animal cells, such as COS cells, cell lines of lymphoid origin such as lymphoma, myeloma (e.g. NSO) and CHO cells, human cells and plant cells in tissue culture.

[73]   A method of producing an antibody comprising culturing the host cell comprising the vector comprising the nucleic acid sequence encoding for the antibodies of the invention under conditions permitting expression of the antibody. Following expression in a host cell maintained in a suitable medium, the polypeptide or peptide to be expressed, such as that encoding the antibodies of the invention, may be isolated from the medium, and purified by methods known in the art. If the polypeptide or peptide is not secreted into the culture medium, the host cells are lysed prior to isolation and purification. A purified antibody is one that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials, which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes, generally have been removed.

[74]   The monoclonal antibodies specific for RON that are secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example protein A-Sepharose, hydrolyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

[75]   In another embodiment, an antibody specific to RON is produced by expressing a nucleic acid encoding the antibody in a transgenic animal, such that the antibody is expressed and can be recovered. For example, the antibody can be expressed

in a tissue specific manner that facilitates recovery and purification. In one such embodiment, an antibody of the invention is expressed in the mammary gland for secretion during lactation. Transgenic animals, include but are not limited to mice, goat, and rabbit.

[76]   The present invention provides for pharmaceutical compositions comprising anti-RON antibodies. In one embodiment, the composition may comprise one or more of the three specific antibodies disclosed herein. It is understood that the anti-RON antibodies of the invention, where used in a mammal for the purpose of prophylaxis or treatment, will be administered in the form of a composition additionally comprising a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Pharmaceutically acceptable carriers can further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the binding proteins. The compositions of the injection can, as is well known in the art, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the mammal.

[77]   Carrier as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or

sorbitol; salt forming counterions such as sodium; and/or nonionic surfactants such as

TWEEN®, polyethylene glycol (PEG), and PLURONICS®.

[78]   The active ingredients may also be entrapped in microcapsules prepared, for

example, by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-

microcapsules and poly(methylmethacylate) microcapsules, respectively, in colloidal drug

delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-

particles, and nanocapsules) or in macroemulsions. The formulations to be used for in

vivo administration must be sterile. This is readily accomplished by filtration through

sterile filtration membranes. Sustained-release preparations maybe prepared. Suitable

examples of sustained-release preparations include semipermeable matrices of solid

hydrophobic polymers containing the antibody, which matrices are in the form of shaped

articles, e.g., films, or microcapsules. Examples of sustained-release matrices include

polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or

poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid

and .gamma. ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic

acid-glycolic acid copolymers such as the LUPRON DEPOT® (injectable microspheres

composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-

hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-

glycolic acid enable release of molecules for over 100 days, certain hydrogels release

proteins for shorter time periods.

[79]   When encapsulated antibodies remain in the body for a long time, they may

denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of

biological activity and possible changes in immunogenicity. Rational strategies can be

devised for stabilization depending on the mechanism involved. For example, if the

aggregation mechanism is discovered to be intermolecular S—S bond formation through

thio-disulfide interchange, stabilization maybe achieved by modifying sulffiydryl residues,

lyophilizing from acidic solutions, controlling moisture content, using appropriate

additives, and developing specific polymer matrix compositions.

[80]   The present invention provides for method of treatments involving administration to a mammal in need thereof a therapeutically effective amount of antibodies or fragments thereof specific to RON. Preferably the mammal is a human. Such antibodies may include chimeric, humanized, murine, rabbit and human antibodies, obtained by various techniques. Preferred antibodies are those having specificity for an epitope on the extracellular domain of RON, including extracellular domains having deletions or other mutations. Preferably the antibody administered is a human antibody, more preferably having at least a single CDR sequence of IMC-41A10, IMC-41B12 or IMC-41A2. Conditions for which these methods are useful include tumors that express RON, inflammatory diseases, hyperproliferative diseases, and diseases of the liver, biliary tract, bile ducts, gall bladder and related hepatobiliary system.

[81]   Treatment means any treatment of a disease in an animal and includes:(1) preventing the disease from occurring in a mammal which may be predisposed to the disease but does not yet experience or display symptoms of the disease; e.g., prevention of the outbreak of the clinical symptoms; (2) inhibiting the disease, e.g., arresting its development; or (3) relieving the disease, e.g., causing regression of the symptoms of the disease.

[82]   In the methods of the present invention, a therapeutically effective amount of an antibody of the invention is administered to a mammal in need thereof. The term administering as used herein means delivering the antibodies of the present invention to a mammal by any method that can achieve the result sought. They can be administered, for example, intravenously or intramuscularly. Although human antibodies of the invention are particularly useful for administration to humans, they can be administered to other mammals as well. The term mammal as used herein is intended to include, but is not limited to, humans, laboratory animals, domestic pets and farm animals. Therapeutically effective amount means an amount of antibody of the present invention that, when administered to a mammal, is effective in producing the desired therapeutic effect, such as inhibiting kinase activity or inhibition of tumor growth.

[83]   The present anti-RON antibodies can be administered for therapeutic treatments to a patient suffering from a tumor or angiogenesis associated pathologic condition in an amount sufficient to prevent, inhibit, or reduce the progression of the tumor or pathologic condition. Progression includes, e.g., the growth, invasiveness, metastases and/or recurrence of the tumor or pathologic condition. An amount adequate to accomplish this is defined as a therapeutically effective dose. Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's own immune system. Dosing schedules will also vary with the disease state and status of the patient, and will typically range from a single bolus dosage or continuous infusion to multiple administrations per day (e.g., every 4-6 hours), or as indicated by the treating physician and the patient's condition. It should be noted, however, that the present invention is not limited to any particular dose.

[84]   A suitable dose for the antibodies of the present invention may be determined based on the *in vivo* data illustrated in the present invention. The *in vivo* experiment used a dose of about 1mg/20grams every three days. The average mouse is about 0.02 Kg and its volume is about 0.008m^2. The average human is about 70Kg, and its volume is about 1.85m^2. A dose of about 200mg/m2 corresponds to about 40mg/Kg into a mouse, which is roughly about 2.6mg/Kg in a human. To put this dose in perspective, another antibody, Erbitux®, is administered at 1 dose pre week of about 250mg/m^2, which is about 6.5 mg/Kg in human. Based on these calculations and experiments, the dose administered to a human is preferably about 1 to about 10mg/Kg, more preferably about 3 to about 8 mg/Kg (1 dose per week). The dose might be similar to that for Erbitux®, about 6 to about 7 mg/Kg.

[85]   The present invention for the first time demonstrates that in vivo inhibition of RON with an antibody that inhibits tumor growth. A RON antibody inhibits HT-29 cells grown sub-cutaneously in nude mice. Preferably, the tumor growth is suppressed at least

about 20%, more preferably at least about 40%. Figure 1 shows about a 50-60% decrease in HT-29 tumor growth over a 40-day period.

[86] RON antibodies can block, preferably at least about 60%, more preferably about 80%, and most preferably about 100%, MSP-induced phosphorylation of RON, MAPK, and AKT (ex. HT-29, Colo205, AGS and DU145). In Figure 3, the bands for Lane 1 and 3 are almost identical, pointing to such complete blocking of phosphorylation. Phosphorylation of MAPK and AKT are considered important for cell proliferation (increase in cell number overtime), migration (movement of cells towards an agent, particularly MSP, *i.e.*, chemo-attraction), invasion (ability to move through a new tissue) and survival respectively. The proliferation of adherent HT-29 and Colo205 cells are preferably inhibited about 20% to about 30%, more preferably about 25% in the presence of a RON antibody and 10% serum. In addition, when HT-29 and Colo205 are grown in soft agar in the presence of A RON antibody and 10% serum, colony formation is preferably inhibited about 60% to about 80%, more preferably about 75% for HT-29, and about 50% to about 70%, more preferably 60% for Colo205.

[87] The present invention is based on the observation that RON specific antibodies can inhibit growth of cancer cells in soft agar and inhibit proliferation while growing as adherent cells in cell culture conditions. A RON antibody can significantly retard the ability of the cancer cell line to form tumors when injected into nude mice, which demonstrates that inhibition of the RON receptor tyrosine kinase negatively influences the proliferation of colon cancer cells.

[88] Using conventional Western blot and flow cytometry procedures, it has been found that RON is expressed in many human tumor cell lines: Colon (HT-29, Colo205, HCT-116, DLD-1, Sw480, Sw620), Pancreatic (BXPC-3, CAPAN-2, ASPC-1, HPAF-II, L3.7p1#7, Hs766T), Prostate (DU-145, PC-3), Stomach (AGS, NCI-N87), Lung (A549, H596) and Liver (HepG2, SNU-182). Accordingly tumors derived from a variety of cell types are therapeutic targets for a RON antibody.

[89]   Tumors to be treated include primary tumors and metastatic tumors, as well as refractory tumors. Refractory tumors include tumors that fail to respond or are resistant to treatment with chemotherapeutic agents alone, antibodies alone, radiation alone or combinations thereof. Refractory tumors also encompass tumors that appear to be inhibited by treatment with such agents, but recur up to five years, sometimes up to ten years or longer after treatment is discontinued.

[90]   Tumors that can be treated include tumors that are not vascularized, or not yet substantially vascularized, as well as vascularized tumors. Examples of solid tumors, which can be accordingly treated, include breast carcinoma, lung carcinoma, colorectal carcinoma, pancreatic carcinoma, glioma and lymphoma. Some examples of such tumors include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors. Other examples include Kaposi's sarcoma, CNS neoplasms, neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases, melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, preferably glioblastoma multiforme, and leiomyosarcoma. Of particular interest are colon, pancreatic, prostate, stomach, lung and liver cancers.

[91]   Accordingly, the human anti-RON antibodies may be effective for treating subjects with vascularized tumors or neoplasms or angiogenic diseases. Such tumors and neoplasms include, for example, malignant tumors and neoplasms, such as blastomas, carcinomas or sarcomas, and highly vascular tumors and neoplasms. Cancers that may be treated by the methods of the present invention include, for example, cancers of the brain, genitourinary tract, lymphatic system, stomach, renal, colon, larynx and lung and bone. Non-limiting examples further include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including lung adenocarcinoma and small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors. The method is also used for treatment

of vascularized skin cancers, including squamous cell carcinoma, basal cell carcinoma, and skin cancers that can be treated by suppressing the growth of malignant keratinocytes, such as human malignant keratinocytes. Other cancers that may be treated include Kaposi's sarcoma, CNS neoplasms (neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases), melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, including glioblastoma multiforme, and leiomyosarcoma.

[92]   In another aspect of the invention, the anti-RON antibodies inhibit tumor-associated angiogenesis. Stimulation of vascular endothelium by Receptor Tyrosine Kinases is associated with vascularization of tumors. Typically, vascular endothelium is stimulated in a paracrine fashion.

[93]   Antineoplastic agents, may be administered separately or as a conjugate to the antibody RON. The anti-neoplastic agents which are presently known in the art or being evaluated can be grouped into a variety of classes including, for example, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, anti survival agents, biological response modifiers, anti-hormones, and anti-angiogenesis agents.

[94]   Many of the known antineoplastic agents are small organic molecules. Embodiments of the invention include methods in which a topoisomerase inhibitor is administered in combination with an antibody that binds to RON. The inhibitors can be inhibitors of topoisomerase I or topoisomerase II. Topoisomerase I inhibitors include irinotecan (CPT-11), aminocamptothecin, camptothecin, DX-8951f, topotecan. Topoisomerase II inhibitors include etoposide (VP-16), and teniposide (VM-26). Other substances are currently being evaluated with respect to topoisomerase inhibitory activity and effectiveness as anti-neoplastic agents. The anti-neoplastic agent can be an alkylating agent or an anti-metabolite. Examples of alkylating agents include, but are not limited to, cisplatin, cyclophosphamide, melphalan, and dacarbazine. Additional small organic molecules include cytotoxic and/or chemotherapeutic agents such as taxol, doxorubicin,

actinomycin-D, methotrexate, gemcitabine, oxyplatin, fluorouracil (5-FU), leucourin (LU), cisplatin, paclitaxel, docetaxel, vinblastine, epothilone, cisplatin/carboplatin and Pegylated adriamycin. The small organic molecules may be administered in combinations such as: (CPT-11; 5-FU; LU); (Paclitaxel; 5-FU); and (CPT-11; 5-FU; LU).

[95]   The anti-neoplastic agent also includes radiation. When the anti-neoplastic agent is radiation, the source of the radiation can be either external (external beam radiation therapy – EBRT) or internal (brachytherapy – BT) to the patient being treated. The dose of anti-neoplastic agent administered depends on numerous factors, including, for example, the type of agent, the type and severity tumor being treated and the route of administration of the agent. It should be emphasized, however, that the present invention is not limited to any particular dose. Radiation may be used in conjunction with other antineoplastic agents.

[96]   In another aspect of the invention, anti-RON antibodies or antibody fragments can be chemically or biosynthetically linked to anti-tumor agents or detectable signal-producing agents, particularly when the antibody is internalized. Anti-tumor agents linked to an antibody include any agents which destroy or damage a tumor to which the antibody has bound or in the environment of the cell to which the antibody has bound. For example, an anti-tumor agent is a toxic agent such as a chemotherapeutic agent or a radioisotope. Suitable chemotherapeutic agents are known to those skilled in the art and include anthracyclines (e.g. daunomycin and doxorubicin), methotrexate, vindesine, neocarzinostatin, cis-platinum, chlorambucil, cytosine arabinoside, 5-fluorouridine, melphalan, ricin and calicheamicin. The chemotherapeutic agents are conjugated to the antibody using conventional methods (See, e.g., Hermentin and Seiler, Behring Inst. Mitt. 82:197-215(1988)).

[97]   The RON antibody may also be administered with radioisotopes to a cancer patient. Suitable radioisotopes for use as anti-tumor agents are also known to those skilled in the art. For example, 131I or 211At is used. These isotopes are attached to the

antibody using conventional techniques (See, e.g., Pedley et al., Br. J. Cancer 68, 69-73(1993)). Alternatively, the anti-tumor agent which is attached to the antibody is an enzyme which activates a prodrug. In this way, a prodrug is administered which remains in its inactive form until it reaches the tumor site where it is converted to its cytotoxin form once the antibody complex is administered. In practice, the antibody-enzyme conjugate is administered to the patient and allowed to localize in the region of the tissue to be treated. The prodrug is then administered to the patient so that conversion to the cytotoxic drug occurs in the region of the tissue to be treated. Alternatively, the anti-tumor agent conjugated to the antibody is a cytokine such as interleukin-2 (IL-2), interleukin-4 (IL-4) or tumor necrosis factor alpha (TNF-α). The antibody targets the cytokine to the tumor so that the cytokine mediates damage to or destruction of the tumor without affecting other tissues. The cytokine is fused to the antibody at the DNA level using conventional recombinant DNA techniques. Interferons may also be used

[98]   The present invention also provides a method of treating a non-cancer hyperproliferative disease in a mammal comprising administering to the mammal an effective amount of the antibody of the present invention. As disclosed herein, "hyperproliferative disease" is defined as a condition caused by excessive growth of non-cancer cells that express a member of the RON family of receptors. The excess cells generated by a hyperproliferative disease express RON at normal levels or they may overexpress RON.

[99]   The types of hyperproliferative diseases that can be treated in accordance with the invention are any hyperproliferative diseases that are stimulated by a ligand of RON or mutants of such ligands. Examples of hyperproliferative disease include psoriasis, actinic keratoses, and seborrheic keratoses, warts, keloid scars, and eczema. Also included are hyperproliferative diseases caused by virus infections, such as papilloma virus infection. For example, psoriasis comes in many different variations and degrees of severity. Different types of psoriasis display characteristics such as pus-like blisters (pustular psoriasis), severe sloughing of the skin (erythrodermic psoriasis), drop-like dots (guttae

psoriasis) and smooth inflamed lesions (inverse psoriasis). The treatment of all types of psoriasis (e. g., psoriasis vulgaris, psoriasis pustulosa, psoriasis erythrodermica, psoriasis arthropathica, parapsoriasis, palmoplantar pustulosis) is contemplated by the invention.

[100]   For treatment of hyperproliferative disease, administration of the antibodies of the invention as described above can be combined with administration of any conventional treatment agent. For example, when the hyperproliferative disease is psoriasis, there are a variety of conventional systemic and topical agents available. Systemic agents for psoriasis include methotrexate, and oral retinoids, such as acitretin, etretinate, and isotretinoin. Other systemic treatments of psoriasis include hydroxyurea, NSAIDS, sulfasalazine, and 6-thioguanine. Antibiotics and antimicrobials can be used to treat or prevent infection that can cause psoriasis to flare and worsen. Topical agents for psoriasis include anthralin, calcipotriene, coal tar, corticosteroids, retinoids, keratolytics, and tazarotene. Topical steroids are one of the most common therapies prescribed for mild to moderate psoriasis. Topical steroids are applied to the surface of the skin, but some are injected into the psoriasis lesions.

[101]   Hyperproliferative disease treatments further include administration of anti-RON antibodies in combination with phototherapy. Phototherapy includes administration of any wavelength of light that reduces symptoms of the hyperproliferative disease, as well as photoactivation of a chemotherapeutic agent (photochemotherapy). For further discussion of treatment of hyperproliferative disorders, see WO 02/11677 (Teufel et al.) (Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists).

[102]   In the present invention, any suitable method or route can be used to administer anti-RON antibodies of the invention, and optionally, to co-administer anti-neoplastic agents and/or antagonists of other receptors. The anti-neoplastic agent regimens utilized according to the invention, include any regimen believed to be optimally suitable for the treatment of the patient's neoplastic condition. Different malignancies can require use of specific anti-tumor antibodies and specific anti-neoplastic agents, which will be

determined on a patient to patient basis. Routes of administration include, for example, oral, intravenous, intraperitoneal, subcutaneous, or intramuscular administration. The dose of antagonist administered depends on numerous factors, including, for example, the type of antagonists, the type and severity tumor being treated and the route of administration of the antagonists. It should be emphasized, however, that the present invention is not limited to any particular method or route of administration.

[103]   The anti-RON antibodies, particularly for treatment of cancers, can also be administered with intracellular RTK antagonists that inhibit activity of RTKs or their associated downstream signaling elements that are involved in tumor growth or tumor-associated angiogenesis. The intracellular RTK antagonists are preferably small molecules. Some examples of small molecules include organic compounds, organometallic compounds, salts of organic compounds and organometallic compounds, and inorganic compounds. Atoms in a small molecule are linked together via covalent and ionic bonds; the former is typical for small organic compounds such as small molecule tyrosine kinase inhibitors and the latter is typical of small inorganic compounds. The arrangement of atoms in a small organic molecule may represent a chain, *e.g.* a carbon-carbon chain or carbon-heteroatom chain or may represent a ring containing carbon atoms, *e.g.* benzene or a policyclic system, or a combination of carbon and heteroatoms, *i.e.*, heterocycles such as a pyrimidine or quinazoline. Although small molecules can have any molecular weight they generally include molecules that would otherwise be considered biological molecules, except their molecular weight is not greater than 650 D. Small molecules include both compounds found in nature, such as hormones, neurotransmitters, nucleotides, amino acids, sugars, lipids, and their derivatives as well as compounds made synthetically, either by traditional organic synthesis, bio-mediated synthesis, or a combination thereof. *See e.g.* Ganesan, *Drug Doscov. Today* 7(1): 47-55 (Jan. 2002); Lou, *Drug Discov. Today*, 6(24): 1288-1294 (Dec. 2001).

[104]   More preferably, the small molecule to be used as an intracellular RTK antagonist according to the present invention is an intracellular RON antagonist that

competes with ATP for binding to EGFR's intracellular binding region having a kinase

domain or to proteins involved in the signal transduction pathways of EGFR activation.

Examples of such signal transduction pathways include the ras-mitogen activated protein

kinase (MAPK) pathway, the phosphatidylinosital-3 kinase (PI3K)-Akt pathway, the

stress-activated protein kinase (SAPK) pathway, and the signal transducers and activators

of transcription (STAT) pathways. Non-limiting examples of proteins involved in such

pathways (and to which a small molecule RON antagonist according to the present

invention can bind) include GRB-2, SOS, Ras, Raf, MEK, MAPK, and matrix

metalloproteinases (MMPs).

[105]   The method of treatment described herein, particularly for cancers, may also be

carried out with administration of other antibodies. For example, an antibody against

EGFR, such as Erbitux® (cetuximab), may also be administered, particularly when treating

colon cancer. Erbitux® MAb is a recombinant, human/mouse chimeric, monoclonal

antibody that binds specifically to the extracellular domain of the human EGFR. Erbitux®

is an EGFR antagonist, which blocks ligand binding to EGFR, prevents receptor

activation, and inhibits growth of tumor cells that express EGFR. Erbitux® has been

approved for use in combination with or without irinotecan in the treatment of patients

with epidermal growth factor receptor-expressing, metastatic colorectal cancer who are

refractory or can not tolerate irinotecan-based chemotherapy. Erbitux® has also been

shown to be effective for treatment of psoriasis.

[106]   Other antibodies for combination use include Herceptin® (trastuzumab)

(against breast cancer cells that express HER2, or HER2 expression on other cancer cells)

and Avastin® (bevacizumab) (antibodies that inhibit angiogenesis). Other antibodies are

2F8 and A12, specific to IGFR, which have the following CDR sequences:

Heavy Chain (2F8/A12)

CDR1   SYAIS

CDR2   GIIPIFGTANYAQKFQG

CDR3   APLRFLEWSTQDHYYYYM
        DV

Light Chain (2F8)

CDR1   QGDSLRSYYAS

CDR2   GKNNRPS

CDR3   NSRDNSDNRLI

Light Chain (A12)

CDR1   QGDSLRSYYAT

CDR2   GENKRPS

CDR3   KSRDGSGQHLV

[107]   The method of treatment described herein may also be carried out with administration of other peptides. For example, variants of MSP may be administered where the variants bind to RON but do not activate RON, or at least competitively inhibit MSP. *See e.g.* U.S. Publ. No. 2003/0073656

[108]   The administration of the RON antibodies with other antibodies and/or small organic molecules may occur simultaneously, or separately, via the same or different route.

[109]   Anti-RON antibodies of the invention can be administered with RON antagonists, and/or antagonists of other RTKs, such as antibodies that block RTK ligands or otherwise inhibit the RTKs. An example of other such RTKs include EGFR, c-met and VEGFR.

[110]   In one embodiment of the present invention, an anti-RON antibody is used in combination with a VEGFR antagonist. In one embodiment of the invention, an anti-RON antibody is used in combination with a receptor antagonist that binds specifically to VEGFR-2/KDR receptor (PCT/US92/01300, filed Feb. 20, 1992; Terman et al., Oncogene 6: 1677-1683 (1991)). In another embodiment, an anti-RON antibody is used in

combination with a receptor antagonist that binds specifically to VEGFR-1/Flt-1 receptor (Shibuya M. et al., Oncogene 5, 519-524 (1990)). Particularly preferred are antigen-binding proteins that bind to the extracellular domain of VEGFR-1 or VEGFR-2 and block binding by ligand (VEGF or PlGF), and/or inhibit VEGF-induced or PlGF-induced activation. For example, Mab IMC-1121 binds to soluble and cell surface-expressed KDR. Mab IMC-1121 comprises the V_H and V_L domains obtained from a human Fab phage display library. (See WO 03/075840) In another example, ScFv 6.12 binds to soluble and cell surface-expressed Flt-1. ScFv 6.12 comprises the V_H and V_L domains of mouse monoclonal antibody MAb 6.12. A hybridoma cell line producing MAb 6.12 has been deposited as ATCC number PTA-3344.

[111]   Another example of such an RTK is insulin-like growth factor receptor (IGFR). In certain tumor cells, inhibition of RTK function can be compensated by upregulation of other growth factor receptor signaling pathways, and particularly by RON stimulation. Further, inhibition of IGFR signaling results in increased sensitivity of tumor cells to certain therapeutic agents. Stimulation of either RON or IGFR results in phosphorylation of common downstream signal transduction molecules, including Akt and p44/42, although to different extents. Accordingly, in an embodiment of the invention, an IGFR antagonist (*e.g.*, an antibody that binds to IGF or IGFR and inhibits the receptor) is coadministered with an antibody of the invention, thereby blocking a second input into the common downstream signaling pathway (*e.g.*, inhibiting activation of Akt and/or p44/42). An example of a human antibody specific for IGFR is IMC-A12 (See WO 2005/016970).

[112]   Another receptor that may be targeted in combination with RON is EGFR. EGFR may be targeted with an antibody such as Erbitux® as described above, or with a small organic molecule. One example of a small molecule RTK antagonist is IRESSA™ (ZD1939), which is a quinozaline derivative that functions as an ATP-mimetic to inhibit EGFR. *See* U.S. Patent No. 5,616,582 (Zeneca Limited); WO 96/33980 (Zeneca Limited) at p. 4; *see also*, Rowinsky *et al.*, Abstract 5 presented at the 37th Annual Meeting of ASCO, San Francisco, CA, 12-15 May 2001; Anido *et al.*, Abstract 1712 presented at the

37th Annual Meeting of ASCO, San Francisco, CA, 12-15 May 2001. Another examples of a small molecule EGFR antagonist is TARCEVA™ (OSI-774), which is a 4-(substitutedphenylamino)quinozaline derivative [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]- (3-ethynyl-phenyl)amine hydrochloride] EGFR inhibitor. *See* WO 96/30347 (Pfizer Inc.) at, for example, page 2, line 12 through page 4, line 34 and page 19, lines 14-17. *See also* Moyer *et al.*, *Cancer Res.*, 57: 4838-48 (1997); Pollack *et al.*, *J. Pharmacol.*, 291: 739-48 (1999). TARCEVA™ may function by inhibiting phosphorylation of EGFR and its downstream PI3/Akt and MAP (mitogen activated protein) kinase signal transduction pathways resulting in p27-mediated cell-cycle arrest. *See* Hidalgo *et al.*, Abstract 281 presented at the 37th Annual Meeting of ASCO, San Francisco, CA, 12-15 May 2001. The above small organic molecules may also inhibit RON.

[113]   Other examples of growth factor receptors involved in tumorgenesis are the receptors for platelet-derived growth factor (PDGF), nerve growth factor (NGF), and fibroblast growth factor (FGF). These receptors may be targeted in combination with RON.

[114]   In another embodiment, the RON antagonist can be administered in combination with one or more suitable adjuvants, such as, for example, cytokines (IL-10 and IL-13, for example) or other immune stimulators, such as, but not limited to, chemokine, tumor-associated antigens, and peptides.

[115]   In a combination therapy, the anti-RON antibody is administered before, during, or after commencing therapy with another agent, as well as any combination thereof, i.e., before and during, before and after, during and after, or before, during and after commencing the anti-neoplastic agent therapy. For example, the anti-RON antibody can be administered between 1 and 30 days, preferably 3 and 20 days, more preferably between 5 and 12 days before commencing radiation therapy. In a preferred embodiment of the invention, chemotherapy is administered concurrently with or, more preferably, subsequent to antibody therapy.

[116]   The invention further contemplates RON antibodies or antibody fragments of the invention to which target or reporter moieties are linked. Target moieties are first members of binding pairs. Anti-tumor agents, for example, are conjugated to second members of such pairs and are thereby directed to the site where the antigen-binding protein is bound. A common example of such a binding pair is avidin and biotin. In a preferred embodiment, biotin is conjugated to an antigen-binding protein of the invention, and thereby provides a target for an anti-tumor agent or other moiety which is conjugated to avidin or streptavidin. Alternatively, biotin or another such moiety is linked to an antigen-binding protein of the invention and used as a reporter, for example in a diagnostic system where a detectable signal-producing agent is conjugated to avidin or streptavidin.

[117]   Detectable signal-producing agents are useful in vivo and in vitro for diagnostic purposes. The signal producing agent produces a measurable signal which is detectable by external means, usually the measurement of electromagnetic radiation. For the most part, the signal producing agent is an enzyme or chromophore, or emits light by fluorescence, phosphorescence or chemiluminescence. Chromophores include dyes which absorb light in the ultraviolet or visible region, and can be substrates or degradation products of enzyme catalyzed reactions.

[118]   Moreover, included within the scope of the present invention is use of the present antibodies *in vivo* and *in vitro* for investigative or diagnostic methods, which are well known in the art. The diagnostic methods include kits, which contain antibodies of the present invention. Such kits might be useful for identification of individuals at risk for certain type of cancers by detecting over-expression of RON on cells of such individuals. Additionally, the antibodies of the present invention may be used in the laboratory for research due to their ability to identify RON.

[119]   The present invention also includes kits for inhibiting tumor growth and/or tumor-associated angiogenesis comprising a therapeutically effective amount of a human anti-EGFR antibody. The kits can further contain any suitable antagonist of, for example, another growth factor receptor involved in tumorigenesis or angiogenesis (e.g., VEGFR-

1/Flt-1, VEGFR-2, PDGFR, IGFR, NGFR, EGFR, FGFR, etc, as described above). Alternatively, or in addition, the kits of the present invention can further comprise an anti-neoplastic agent. Examples of suitable anti-neoplastic agents in the context of the present invention have been described herein. The kits of the present invention can further comprise an adjuvant; examples have also been described above.

[120]   The present invention further provides the method of identifying and isolating antibodies having the same functionality of IMC-41A2, IMC-41A10 or IMC-41B12, or fragments thereof, wherein the screening of the library includes providing an affinity matrix having RON containing ligand binding function bound to a solid support, contacting the affinity matrix with the library of antibody fragments, and separating the antibody fragments that bind to the affinity matrix from the antibody fragments that do not bind the affinity matrix.

[121]   By solid support is meant a non-aqueous matrix to which the RON can adhere. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Pat. No. 4,275,149.

[122]   All patents and literature references cited in the present specification are hereby incorporated by reference in their entirety.

EXAMPLES

[123]   The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. The examples do not include detailed descriptions of conventional methods, such as those employed in the construction of vectors and plasmids, the insertion of genes encoding polypeptides into

such vectors and plasmids, or the introduction of plasmids into host cells. Such methods

are well known to those of ordinary skill in the art and are described in numerous

publications including Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular

Cloning: A laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press.

[124]   MATERIALS AND METHODS
Development and Characteristics of Two Fab Anti-RON Antibodies

(IMC-41A10 and IMC-41B12)

[125]   Selection of human anti-RON Fab antibodies from a phage display library. A

large human Fab phage display library containing 3.7 x 10^{10} clones was used for the

selection. The library stock was grown to log phase, rescued with M13K07 helper phage

and amplified overnight in 2YTAK medium (2YT containing 100 µg/ml of ampicillin and

50 g/ml of kanamycin) at 30°C. The phage preparation was precipitated in 4% PEG/0.5M

NaCl, resuspended in 3% fat-free milk/PBS containing 500 µg/ml of Fc protein and

incubated at 37°C for 1 h to capture phage displaying anti-Fc Fab fragments and to block

other nonspecific binding.

[126]   RON-Fc (10 µg/ml in PBS; Sigma-Aldrich) coated Maxisorp Star tubes (Nunc,

Rosklide, Denmark) were first blocked with 3% milk/PBS at 37°C for 1 h, and then

incubated with the phage preparation at RT for 1 h. The tubes were washed 20 times with

PBST (PBS containing 0.1% Tween-20) followed by 20 washes with PBS. The bound

phage was eluted at RT for 10 min with 1 ml of a freshly prepared solution of 100 mM

triethylamine (Sigma, St. Louis, MO). Phage were eluted with 100 mM triethylamine and

neutralized with Tris.HCl, pH7.4 and used to re-infect incubated with 10 ml of mid-log

phase TG1 cells at 37°C for 30 min without shaking followed by a 30 min shake. The

infected TG1 cells were pelleted and plated onto several large 2YTAG plates and

incubated overnight at 30°C. All the colonies grown on the plates were scraped into 3 to 5

ml of 2YTA medium, mixed with glycerol (final concentration: 10%), aliquoted and

stored at –70°C. For the next round of selection, 100 µl of the phage stock was added to

25 ml of 2YTAG medium and grown to mid-log phase. The culture was rescued with

M13K07 helper phage, amplified, precipitated, and used for selection following the
procedure described above, with reduced concentrations of RON-Fc immobilized on the
immunotube and increased number of washes after the binding process.

[127]   ELISA to Detect Phage Fab Antibodies from Phage that Bind to RON.
Individual TG1 clones were picked and grown at 37°C in 96 well plates and rescued with
M13K07 helper phage as described above. The amplified phage preparation was blocked
with 1/6 volume of 18% milk/PBS at RT for 1 h and 100 µl/well was added to Maxi-sorp
96-well microtiter plates (Nunc) coated with RON-Fc or Fc (1 µg/ml x 100 µl). After
incubation at RT for 1.5 h the plates were washed 3 times with PBST and incubated with a
1:5000 dilution of a mouse anti-M13 phage-HRP conjugate (Amersham Pharmacia
Biotech, Piscataway, NJ). The plates were washed 5 times, TMB peroxidase substrate
(KPL, Gaithersburg, MD) added, and the absorbance at 450 nm read using a microplate
reader (Molecular Device, Sunnyvale, CA).

[128]   Expression and purification of the soluble Fab fragments. Plasmids of
individual clones were used to transform a nonsuppressor Escherichia coli host HB2151.
Expression of the Fab fragments in HB2151 was induced by culturing the cells in 2YTA
medium containing 1 mM isopropyl-1-thio-D-galactopyranoside (Sigma) at 30°C. A
periplasmic extract of the cells was prepared by resuspending the cell pellet in 25 mM Tris
(pH 7.5) containing 20% (w/v) sucrose, 200 mM NaCl, 1 mM EDTA and 0.1 mM
phenylmetnylsulfonyl fluoride (PMSF), followed by incubation at 4°C with gentle shaking
for 1 hr. After centrifugation at 15,000 rpm for 15 min, the soluble Fab protein was
purified from the supernatant by affinity chromatography using a Protein G column
following the manufacturer's protocol (Amersham Pharmacia Biotech).

[129]   ELISA to Detect Fab Antibodies That Block the MSP/RON Interaction. Maxi-
sorp 96-well microtiter plates (Nunc) were coated with (1 µg /ml x 100 µl) MSP (R&D
Systems) at RT for 1.5 hours. After washing the wells, they were blocked with 3%
PBS/milk. Anti-RON phage antibodies that were converted to Fab or full IgG were pre-
incubated with RON-Fc (25 ng/well) at RT for 1 hour. The Fab/RON-Fc or IgG/RON-Fc

mixtures were then added to the MSP-coated wells and allowed to incubate for 1.5h at RT. After several washes, a 1:1000 dilution of the anti-human IgG, Fab-specific-HRP conjugated antibody was added to the plates for 1.5h at RT in order to detect the anti-RON Fab or IgG that bound to RON, but that did not block the MSP/RON interaction.

[130]   DNA <u>BstN I pattern analysis and nucleotide sequencing.</u> The diversity of the anti-RON phage Fab clones after each round of selection was analyzed by restriction enzyme digestion patterns (*i.e.,* DNA fingerprints). The Fab gene insert of individual clones was PCR amplified using primers: PUC19 reverse, 5', AGCGGATAACAATTTCACACAGG 3'; and fdtet seq, 5' GTCGTCTTTCCAGACGTTAGT 3'. The amplified product was digested with a frequent-cutting enzyme, *Bst*N I, and analyzed on a 3% agarose gel. DNA sequences of representative clones from each digestion pattern were determined by dideoxynucleotide sequencing.

[131]   Cloning of Fab Heavy and Light Chain Fragments to Produce IgG Antibodies. The DNA sequences encoding the heavy and light chain genes from the IMC-IMC-41A10 and IMC-41B12 Fab candidates were amplified by PCR for cloning into glutamine synthetase system expression vectors (Lonza Biologics plc, Slough, Berkshire, United Kingdom). The DNA and protein sequences for the variable regions of the IMC-41A10 and IMC-41B12 heavy and light chains are shown in Figure 1. Engineered immunoglobulin expression vectors were stably transfected in NS0 cells using glutamine synthetase selection, and clones were screened for antibody expression by anti-Fc ELISA. Full-length IgG1 antibody was purified by protein A affinity chromatography (Poros A; PerSeptive Biosystems Inc., Foster City, CA).

[132]   BIAcore Analysis.The binding kinetics of soluble Fab and antibody proteins to RON was determined by using a BIACORE 3000 (BIAcore, Piscataway, NJ). Recombinant RON-Fc was immobilized onto a sensor chip, and Fab or antibody was injected at various concentrations. Sensorgrams were obtained and evaluated using BIA Evaluation 2.0 software to determine rate constants. The affinity constant, K_D, was

calculated from the ratio of the rate constants K_{off}/K_{on}. The "Kon, $M^{-1}.S^{-1}$" and "Koff, S^{-1}" rates of the interaction were used to determine the affinity (Kd, M) of the antibody/receptor interaction. The Kd, Kon, and Koff rates for IMC-41A10 were 1.5e-9, 8.4e4 and 1.3e-4. For IMC-41B12, they were: 1e-10, 1.7e6 and 1.7e-4.

[133]   Flow Cytometry of RON Cell Surface Expression. One million cells from adherent cancer cell lines were incubated in PBS+5%FCS for 30 minutes with 5 micrograms IMC-41A10 at 4°C. After a wash in PBS+5%FCS, cells were incubated with anti-human IgG phycoerythrin-conjugated secondary antibody (Jackson Immuno Research) for 30 minutes at 4°C. After a PBS+5%FCS wash, cells were analyzed by flow cytometry using a FACSvantage SE flow cytometer (Becton Dickinson).

[134]   Western Blotting and Immunoprecipitation. Cells were plated into 10-cm or 6-well culture dishes and grown to 70–80% confluence. Monolayers were washed twice in PBS and cultured overnight in serum-free medium. Antibody was then added in fresh serum-free media and incubated at 37°C for 30–60 min. Cells were incubated with ligand for 10 min and then placed on ice and washed with ice-cold PBS. The cells were lysed in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM Na_3VO_4, 1 μg/ml leupeptin, 1 μg/ml pepstatin, and 1 μg/ml aprotinin on ice for 10 min. The lysate was clarified by centrifugation at 4°C. Solubilized RON was then immunoprecipitated from the lysate. Antibody RON, clone C-20 (Santa Cruz Biotechnology, Santa Cruz, CA) or IMC-41A10 were incubated with 400 μl of lysate at 4 μg/ml overnight at 4°C. Immune complexes were precipitated by the addition of protein A-agarose beads for 2 h at 4°C, pelleted, and washed three times with lysis buffer. Immunoprecipitates bound to the protein A-agarose beads were stripped into denaturing gel sample buffer. Lysates or immunoprecipitates were processed for denaturing gel electrophoresis and run on a 4–12% acrylamide gel and blotted to nitrocellulose membrane by Western blot. Tyrosine-phosphorylated protein was detected on the blot using an anti-phosphoRON antibody (Biosource) and an anti-mouse-horseradish peroxidase secondary antibody. RON was detected with monoclonal antibody

RON C-20 (Santa Cruz Biotechnology. Phospho-Akt and total Akt antibodies were

obtained from PharMingen (BD Biosciences, San Diego, CA). For MAPK

phosphorylation, phospho-p44/42 and total p44/42 antibodies were purchased from Cell

Signaling Technology). Bands were visualized with the enhanced chemiluminescence

reagent (Amersham Pharmacia Biotech) on X-ray film (Eastman Kodak, Rochester, NY).

[135]   ELISA for Determination of IC50 and ED50 The ability of the anti-RON

antibodies, IMC-41A10 and IMC-41B12, to bind to recombinant human RON receptor

and to block the MSP/RON interaction were measured using ELISA. With the receptor

immobilized to an ELISA plate, the ED50 values for binding of IMC-41A10 and IMC-

41B12 to RON were 0.15 nM and 0.10 nM respectively. Using the same ELISA format,

an IC50 value of 2 nM was shared by IMC-41A10 and IMC-41B12 for their ability to

block the MSP/RON interaction.

[136]   Cell Proliferation Assay. For proliferation inhibition, 10,000 cells from cancer

cell lines were seeded into 24-well plates in complete medium. After 24 h, 100 nM anti-

RON IMC-41A10 antibody was added to plates in triplicate and allowed to culture for an

additional 3 days. The total number of cells (bound and suspension) for each well was

determined using a Coulter counter.

[137]   Human Tumor Xenograft Model. Tumor xenografts were established by s.c.

injection of 5 x 10^6 HT-29 cells mixed in Matrigel (Collaborative Research Biochemicals,

Bedford, MA) into the left flank of 5–6-week-old female athymic (nu/nu) mice (Charles

River Laboratories, Wilmington, MA). Tumors were allowed to reach 150–300 mm^3 in

size, and then mice were randomized into groups of 12 animals each. Mice were treated by

i.p. injection every 3 days with control antibody (human IgG) or monoclonal anti-RON

IMC-41A10 antibody at a dose of 1 mg. Treatment of animals was continued for the

duration of the study. Tumors were measured twice each week with calipers, and tumor

volumes were calculated by the following formula: (π/6 (w1 x w2 x w2)), where w1

represents the largest tumor diameter, and w2 represents the smallest tumor diameter.

Tumor volumes were analyzed using the Mann-Whitney U test and computed using the statistical package in SigmaStat (version 2.03; Jandel Scientific, San Rafeal, CA).

1)   Wang, M. H., Kurtz, A. L., Chen, Y. (2000b). Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. *Carcinogenesis* **21**, 1507–1512.

2)   Leonard, E. J., Danilkovitch, A. (2000). Macrophage stimulating protein. *Adv. Cancer Res.* **77**, 139–167.

3)   Skeel, A., Leonard, E. J. (1994). Action and target cell specificity of human macrophage-stimulating protein (MSP). *J. Immunol.* **152**, 4618–4623.

4)   Leonard, E. J., Skeel, A. (1976). A serum protein that stimulates macrophage movement, chemotaxis and spreading. *Exp. Cell Res.* **102**, 434–438.

5)   Iwama, A., Wang, M. H., Yamaguchi, N., Ohno, N., Okano, K., Sudo, T., Takeya, M., Gervais, F., Morissette, C., Leonard, E. J. (1995). Terminal differentiation of murine resident peritoneal macrophages is characterized by expression of the STK protein tyrosine kinase, a receptor for macrophage-stimulating protein. *Blood* **86**, 3394–3403.

6)   Wang, M. H., Cox, G. W., Yoshimura, T., Sheffler, L. A., Skeel, A., Leonard, E. J. (1994a). Macrophage-stimulating protein inhibits induction of nitric oxide production by endotoxin- or cytokine-stimulated mouse macrophages. *J. Biol. Chem.* **269**, 14027–14031.

7)   Wang, M. H., Dlugosz, A. A., Sun, Y., Suda, T., Skeel, A., Leonard, E. J. (1996a). Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes. *Exp. Cell Res.* **226**, 39–46.

8)   Wang, M. H., Montero-Julian, F. A., Dauny, I., Leonard, E. J. (1996b). Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein. *Oncogene* **13**, 2167–2175.

9)   Okino, T., Egami, H., Ohmachi, H., Takai, E., Tamori, Y., Nakagawa, K., Nakano, S., Akagi, J., Sakamoto, O., Suda, T., Ogawa, M. (1999). Presence of RON receptor tyrosine kinase and its splicing variant in malignant and non-malignant human colonic mucosa. *Int. J. Oncol.* **15**, 709–714.

10)   Chen, Y. Q., Zhou, Y. Q., Angeloni, D., Kurtz, A. L., Qiang, X. Z., Wang, M. H. (2000). Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. *Exp. Cell Res.* **261**, 229–238.

11)   Wang, M. H., Kurtz, A. L., Chen, Y. (2000b). Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. *Carcinogenesis* **21**, 1507–1512.

12)   Willett, C. G., Wang, M. H., Emanuel, R. L., Graham, S. A., Smith, D. I., Shridhar, V., Sugarbaker, D. J., Sunday, M. E. (1998). Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration. *Am. J. Respir. Cell Mol. Biol.* **18**, 489–496.

13)   Maggiora, P., Marchio, S., Stella, M. C., Giai, M., Belfiore, A., De Bortoli, M., Di
        Renzo, M. F., Costantino, A., Sismondi, P., Comoglio, P. M. (1998).
        Overexpression of the RON gene in human breast carcinoma. *Oncogene* **16**, 2927–
        2933.

14)   Chen, YQ, Zhou, YQ, Fisher, JH, Wang M-H. (2002). Targeted expression of the
        receptor tyrosine kinase RON in distal lung epithelial cells results in multiple
        tumor formation: oncogenic potential of RON in vivo. *Oncogene* 21, 6382-6386.

15)   Chen YQ, Zhou YQ, Fu LH, Wang D, Wang MH. (2002). Multiple pulmonary
        adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine
        kinase. Carcinogenesis 23, 1811-1819.

16)   Santoro MM, Collesi C, Grisendi S, Gaudino G, Comoglio P (1996). Constitutive
        Activation of the RON Gene Promotes Invasive Growth but Not Transformation.
        Molecular and Cellular Biology, Dec. 1996, p. 7072-7083.

What is claimed is:

1.   A monoclonal antibody, or fragment thereof, specific for RON comprising one or more heavy chain CDR sequences selected from the group consisting of SEQ ID NO: 2 (SYAMH) for CDR1; SEQ ID NO: 4 (VISYDGSNKYYADSVKG) for CDR2 and SEQ ID NO: 6 for CDR3 (FSGWPNNYYYYGMDV).

2.   The monoclonal antibody, or fragment thereof, of claim 1, wherein the antibody comprises the CDR1, CDR2 and CDR3 sequences.

3.   A monoclonal antibody, or a fragment thereof, specific for RON comprising one or more light chain CDR sequences selected from the group consisting of SEQ ID NO: 11 for CDR1 (RSSQSLLHSNGFNYVD); SEQ ID NO: 13 for CDR2 (FGSYRAS) and SEQ ID NO: 15 for CDR3 (MQALQTPPWT).

4.   The monoclonal antibody, or fragment thereof, of claim 3, wherein the antibody comprises the CDR1, CDR2 and CDR3 sequences.

5.   The monoclonal antibody, or fragment thereof, of claims 4, wherein the antibody comprises a heavy chain variable region sequence of SEQ ID NO:7 or a light chain variable region sequence of SEQ ID NO:16.

6.   The monoclonal antibody, or fragment thereof, of claim 5, wherein the antibody comprises both the heavy and light chain with said sequences.

7.   The monoclonal antibody, or fragment thereof, of claim 6, wherein the antibody comprises a heavy chain sequence of SEQ ID NO: 9 and a light chain sequence of SEQ. ID. NO. 18.

8.   A monoclonal antibody, or a fragment thereof, specific for RON comprising one or more light chain CDR sequences selected from the group consisting of SEQ ID NO: 50 for CDR1 (RSSQSLLHSNGYNYLD); SEQ ID NO: 52 for CDR2 (LGSNRAS) and SEQ ID NO: 54 for CDR3 (MQALQTPRT).

9.   The monoclonal antibody, or fragment thereof, of claim 8, wherein the antibody comprises the CDR1, CDR2 and CDR3 sequences.

10.   The monoclonal antibody, or fragment thereof, of claims 9, wherein the antibody comprises a heavy chain variable region sequence of SEQ ID NO:41 or a light chain variable region sequence of SEQ ID NO:42.

11.   The monoclonal antibody, or fragment thereof, of claim 10, wherein the antibody comprises both the heavy and light chain with said sequences.

12.   The monoclonal antibody, or fragment thereof, of claim 11, wherein the antibody comprises a heavy chain sequence of SEQ ID NO 56 and a light chain sequence of SEQ ID NO 58.

13.   A monoclonal antibody, or fragment thereof, specific for RON comprising one or more heavy chain CDR sequences selected from the group consisting of SEQ ID NO: 20 (SHYWS) for CDR1; SEQ ID NO: 23 (YIYYSGSTNYNPSLKS) for CDR2 and SEQ ID NO: 24 for CDR3 (IPNYYDRSGYYPGYWYFDL).

14.   The monoclonal antibody, or fragment thereof, of claim 13, wherein the antibody comprises the CDR1, CDR2 and CDR3 sequences.

15.   A monoclonal antibody, or fragment thereof, specific for RON comprising one or more light chain CDR sequences selected from the group consisting of SEQ ID NO: 16 for CDR1 (TLRSGFNVDSYRIS); SEQ ID NO: 17 for CDR2 (YKSDSDK) and SEQ ID NO: 18 for CDR3 (MIWHSSAWV).

16.   The monoclonal antibody, or fragment thereof, of claim 15, wherein the antibody comprises the CDR1, CDR2 and CDR3 sequences.

17.   The monoclonal antibody, or fragment thereof, of claims 16, wherein the antibody comprises a heavy chain variable region sequence of SEQ ID NO:25 or a light chain variable region sequence of SEQ ID NO:35.

18.   The monoclonal antibody, or fragment thereof, of claim 17, wherein the antibody comprises both the heavy and light chain variable regions with said sequences.

19.   The monoclonal antibody, or fragment thereof, of claim 18, wherein the antibody has a heavy chain sequence of SEQ ID NO: 27

20.   The monoclonal antibody, or fragment thereof, of claim 19, wherein the antibody has a light chain sequence of SEQ ID NO: 37 or 39.

21.   An isolated nucleic acid molecule comprising the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, 3, 5, 8, 10, 12, 14, 17, 19, 21, 23, 26, 29, 31, 33, 36, 38, 43, 45, 4749, 51, 53, 55 and 57.

22.   An expression vector comprising the nucleic acid of claim 21 operably linked to a control sequence.

23.   A host cell comprising the expression vector of claim 22.

24.   A method for producing an antibody comprising culturing the host cell of claim 23 under conditions permitting expression of the antibody.

25.   A pharmaceutical composition comprising the monoclonal antibody, or fragment thereof, of any one of claims 1 through 20 and a pharmaceutically acceptable carrier.

26.   A method for detecting the presence of RON in a sample comprising contacting said sample with the antibody, or a fragment thereof of any of claims 1 to 20 to obtain specific binding, and detecting such binding.

27.   A method for inhibiting growth of mammalian tumor cells that express RON, comprising administering to a mammal an effective amount of an antibody or a fragment thereof specific for RON.

28.   A method for inhibiting metastatic activity of mammalian tumor cells that express RON, comprising administering to a mammal an effective amount of an antibody or a fragment thereof specific for RON.

29.   A method for treating inflammation mediated by RON activity in a mammal comprising administering to the mammal an antibody or an antibody fragment specific for RON.

30.   The method for any one of claims 27 to 29, further comprising administering a small organic molecule, wherein the small organic molecule is a chemotherapeutic agent, anti-angiogenesis agent or inhibitor of RON activation.

31.   The method of claim 30, wherein the antibody is conjugated to the small organic molecule.

32.   The method for any one of claims 27 to 31, further comprising administering one or more antibodies specific to a receptor tyrosine kinase.

33.   The method for claim 32, wherein the receptor tyrosine kinase is EGFR or VEGFR.

34.   The method for any one of claims 27, 28, 30-33, wherein the tumor cells are selected from the group consisting of colon, pancreatic, prostate, stomach, lung, liver, ovarian, kidney, breast and brain.

35.   The method of claim 34, wherein the tumor cell is from the colon.

36.   The method of any one of claims 27, 28, 30-33, wherein the tumor cell is an epithelial cell or a neuroendocrine cell.

37.   The method of any one of claims 27 to 36, wherein the RON specific antibody or a fragment thereof is a human antibody.

38.   The method of any one of claims 27 to 37, wherein the antibody blocks binding of MSP to RON.

39.   The method of any one of claims 27 to 38, wherein the antibody is administered at a dose of about 1 to about 10mg/Kg.

40.   The method of claim 39, wherein the antibody is administered at a dose of about 3 to about 8 mg/Kg.

41.   The method of any one of claims 27 to 40, wherein the antibody comprises one or more heavy chain CDR sequences selected from the group consisting of SEQ ID NO: 2 (SYAMH) for CDR1; SEQ ID NO: 4 (VISYDGSNKYYADSVKG) for CDR2 and SEQ ID NO: 6 for CDR3 (FSGWPNNYYYYGMDV).

42.   The method of any one of claims 41, wherein the antibody comprises the CDR1, CDR2 and CDR3 sequences.

43.   The method of any one of claims 27 to 40, wherein the antibody comprises one or more light chain CDR sequences selected from the group consisting of SEQ ID NO: 11 for CDR1 (RSSQSLLHSNGFNYVD); SEQ ID NO: 13 for CDR2 (FGSYRAS) and SEQ ID NO: 15 for CDR3 (MQALQTPPWT).

44.   The method of claim 43, wherein the antibody comprises the CDR1, CDR2 and CDR3 sequences.

45.   The method of claim 44, wherein the antibody comprises a heavy chain variable region sequence of SEQ ID NO:7 or a light chain variable region sequence of SEQ ID NO:16.

46.   The method of any one of claims 27 to 40, wherein the antibody comprises one or more light chain CDR sequences selected from the group consisting of SEQ ID NO: 50 for CDR1 (RSSQSLLHSNGYNYLD); SEQ ID NO: 52 for CDR2 (LGSNRAS) and SEQ ID NO: 54 for CDR3 (MQALQTPRT).

47.   The method of claim 46, wherein the antibody comprises the CDR1, CDR2 and CDR3 sequences.

48.   The method of claim 47, wherein the antibody comprises a heavy chain variable region sequence of SEQ ID NO:41 or a light chain variable region sequence of SEQ ID NO:42.

49.   The method of any one of claims 27 to 40, wherein the antibody comprises one or more heavy chain CDR sequences selected from the group consisting of SEQ ID NO: 20 (SHYWS) for CDR1; SEQ ID NO: 23 (YIYYSGSTNYNPSLKS) for CDR2 and SEQ ID NO: 24 for CDR3 (IPNYYDRSGYYPGYWYFDL).

50.   The method of claim 49, wherein the antibody comprises the CDR1, CDR2 and CDR3 sequences.

51.   The method of any one of claims 27 to 40, wherein the antibody comprises one or more light chain CDR sequences selected from the group consisting of SEQ ID NO: 16 for CDR1 (TLRSGFNVDSYRIS); SEQ ID NO: 17 for CDR2 (YKSDSDK) and SEQ ID NO: 18 for CDR3 (MIWHSSAWV).

52.   The method of claim 51, wherein the antibody comprises the CDR1, CDR2 and CDR3 sequences.

53.   The method of claim 52, wherein the antibody comprises a heavy chain variable region sequence of SEQ ID NO:25 or a light chain variable region sequence of SEQ ID NO:35.

54.   The method of claim 53, wherein the antibody comprises both the heavy and light chain variable regions with said sequences.

55.   The method of any one of claims 54, wherein the antibody has a heavy chain sequence of SEQ ID NO. 27 and a light chain sequence of SEQ ID NO: 37 or 39.

56.   A therapeutic composition for inhibition of growth of tumor cells that express RON in a mammal comprising an antibody, or fragment thereof, specific for RON.

57.   The therapeutic composition of claim 56, wherein the antibody or a fragment thereof a human antibody.

FIGURE 1

41A10 (RON) TREATMENT ON HT29 TUMOR

Tumor Growth is Significantly Different In 41A10 vs hIgG and Saline Groups (p<0.001; Repeated Measures ANOVA)

Mean +/- SEM

DAYS OF TREATMENT

FIGURE 2

SEQ. ID. No. 1 (CDR1 cDNA sequence of heavy chain of IMC-41A10)
AGCTATGCTATGCAC

SEQ. ID. No. 2 (CDR1 amino acid sequence of heavy chain of IMC-41A10)
SYAMH

SEQ. ID. No. 3 (CDR2 cDNA sequence of heavy chain region of IMC-41A10)
GTTATATCATATGATGGAAGTAATAAATACTACGCAGACTCCGTGAAGGGC

SEQ ID. No. 4 (CDR2 heavy chain amino acid sequence of IMC-41A10)
VISYDGSNKYYADSVKG

SEQ. ID. No. 5 (CDR3 cDNA sequence of heavy chain of IMC-41A10)
TTCAGTGGCTGGCCCAACAACTACTACTACTACGGTATGGACGTC

SEQ ID. No. 6 (CDR3 amino acid sequence of heavy chain of IMC-41A10)
FSGWPNNYYYYGMDV

SEQ ID. NO. 7 (Amino acid sequence of Heavy chain variable region of IMC-41A10)
EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARFSGWPNNYYYYGMDVWGQGTTV
TVSS

SEQ. ID. No. 8 (Heavy chain cDNA sequence of IMC-41A10 (Ig gamma1))
ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACTGGAGTACATTCAGAG
GTCCAGCTGGTGCAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCC
TGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCTCCA
GGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTACGCA
GACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTG
CAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGGTTCAGTGGC
TGGCCCAACAACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACC
GTCTCAAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGC
ACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTG
ACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTA
CAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGC
ACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAA
GTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTC
CTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAG
TTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG

FIGURE 2 (Cont'd)

CAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTG
AATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAA
ACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCC
CGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCC
AGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACG
CCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAG
AGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAAC
CACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA

SEQ ID. NO. 9 (Heavy chain amino acid sequence of IMC-41A10)
EVQLVQSGGGLVKPGGSLRLSCAASGFTFS<u>SYAMH</u>WVRQAPGKGLEWVA<u>VISYDGSNKYY</u>
<u>ADSVKG</u>RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR<u>FSGWPNNYYYYGMDV</u>WGQGTTV
TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP
SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ. ID. No. 10 (CDR1 cDNA sequence of light chain of IMC-41A10)
AGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATTCAACTATGTGGAT

SEQ. ID. No. 11 (CDR1 amino acid sequence of Light chain of IMC-41A10)
RSSQSLLHSNGFNYVD

SEQ. ID. No. 12 (CDR2 cDNA sequence of light chain of IMC-41A10)
TTCGGTTCTTATCGGGCCTCC

SEQ. ID. No. 13 (CDR2 amino acid sequence of light chain of IMC-41A10)
FGSYRAS

SEQ. ID. No. 14 (CDR3 cDNA sequence of light chain of IMC-41A10)
ATGCAAGCTCTGCAAACTCCTCCCTGGACG

SEQ. ID. No. 15 (CDR3 amino acid sequence of IMC-41A10)
MQALQTPPWT

SEQ ID. No. 16 (Amino acid sequence of variable region of light chain of IMC-41A10)
DVVMTQSPLSLPVTPGEPASISC<u>RSSQSLLHSNGFNYVD</u>WYLQKPGQSPHLLIY<u>FGSYRA</u>
<u>S</u>GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC<u>MQALQTPPWT</u>FGQGTKVEIR

FIGURE 2 (Cont'd)

SEQ. ID. No. 17 (<u>IMC-41A10</u> Light chain cDNA sequence (Ig kappa))

ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACTGGAGTACATTCAGAT
GTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATC
TCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATTCAACTATGTGGATTGGTAC
CTGCAGAAGCCAGGGCAGTCTCCACACCTCTTGATCTATTTCGGTTCTTATCGGGCCTCC
GGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGC
AGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTGCAAACTCCTCCC
TGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAGACGTACGGTGGCTGCACCATCTGTC
TTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTG
CTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAA
TCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTC
AGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAA
GTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG

SEQ ID. No. 18 (Amino acid sequence of light Chain of <u>IMC-41A10</u>)

DVVMTQSPLSLPVTPGEPASISC<u>RSSQSLLHSNGFNYVD</u>WYLQKPGQSPHLLIY<u>FGSYRA</u>
SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC<u>MQALQTPPWT</u>FGQGTKVEIRRTVAAPS
VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS
LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SEQ ID. No. 19 (CDR1 CDNA sequence of heavy chain of <u>IMC-41B12</u>)
AGTCACTACTGGAGT

SEQ ID. No. 20 (CDR1 amino acid sequence of heavy chain of <u>IMC-41B12</u>)
SHYWS

SEQ ID. No. 21 (CDR2 CDNA sequence of heavy chain of <u>IMC-41B12</u>)
TACATCTATTACAGTGGGAGCACCAACTACAACCCCTCCCTCAAGAGT

SEQ ID. No. 22 (CDR2 amino acid sequence heavy chain of <u>IMC-41B12</u>)
YIYYSGSTNYNPSLKS

SEQ ID. No. 23 (CDR3 CDNA sequence of heavy chain of <u>IMC-41B12</u>)
ATTCCCAACTACTATGATAGAAGTGGTTATTATCCCGGTTACTGGTACTTCGATCTC

SEQ ID. No. 24 (CDR3 amino acid sequence of heavy chain of <u>IMC-41B12</u>)
IPNYYDRSGYYPGYWYFDL

FIGURE 2 (Cont'd)

SEQ ID. No. 25 (Variable Region of Heavy Chain IMC-41B12)
QVQLQESGPGLVKPSEILSLTCTVSGGSISSHYWSWVRQPPGKGLEWIGYIYYSGSTNYN
PSLKSRVTISVDTSKNQFSLNLSSVTAADTAVYYCARIPNYYDRSGYYPGYWYFDLWGRG
TLVTVSS

SEQ. ID. No. 26 (IMC-41B12 Heavy chain cDNA sequence) (Ig
gamma1)

ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACTGGAGTACATTCACAG
GTGCAGCTGCAGGAGTCCGGCCCAGGACTGGTGAAGCCTTCGGAGATCCTGTCCCTCACC
TGCACTGTCTCTGGTGGCTCCATCAGTAGTCACTACTGGAGTTGGGTCCGGCAGCCCCCA
GGGAAGGGACTGGAGTGGATTGGGTACATCTATTACAGTGGGAGCACCAACTACAACCCC
TCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAC
CTGAGCTCTGTGACCGCTGCGGACACGGCCGTGTATTATTGTGCGAGAATTCCCAACTAC
TATGATAGAAGTGGTTATTATCCCGGTTACTGGTACTTCGATCTCTGGGGCCGTGGCACC
CTGGTCACCGTCTCAAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCC
TCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCC
GAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCG
GCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGC
AGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTG
GACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCA
CCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTC
ATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCT
GAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCG
CGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTG
CCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGC
TTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTAC
AAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACC
GTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCT
CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA

SEQ ID. No. 27 (Amino acid sequence of Heavy Chain of IMC-
41B12)
QVQLQESGPGLVKPSEILSLTCTVSGGSISSHYWSWVRQPPGKGLEWIGYIYYSGSTNYN
PSLKSRVTISVDTSKNQFSLNLSSVTAADTAVYYCARIPNYYDRSGYYPGYWYFDLWGRG
TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCP
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT
LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID. No. 29 (CDR1 cDNA sequence of lambda or kappa light
chain of IMC-41B12)
TLRSGFNVDSYRIS

FIGURE 2 (Cont'd)

SEQ ID. No. 30 (CDR1 amino acid sequence of lambda or kappa
light chain of <u>IMC-41B12</u>)
ACCTTGCGCAGTGGCTTCAATGTTGATTCCTACAGGATATCC

SEQ ID. No. 31 (CDR2 cDNA sequence of lambda or kappa light
chain of <u>IMC-41B12</u>)
TACAAATCAGACTCAGATAAG
SEQ ID. No. 32 (CDR2 amino acid sequence of lambda or kappa
light chain of <u>IMC-41B12</u>)
YKSDSDK

SEQ ID. No. 33 (CDR3 cDNA sequence of lambda or kappa light
chain of <u>IMC-41B12</u>)
ATGATTTGGCACAGCAGCGCTTGGGTG

SEQ ID. No. 34 (CDR3 amino acid sequence of LAMBDA OR KAPPA
light chain of <u>IMC-41B12</u>)
MIWHSSAWV

SEQ ID. No. 35 (variable region amino acid sequence of light
chain OF <u>IMC-41B12</u>)
QAVLTQPSSLSAPPGASASLTCTLRSGFNVDSYRISWYQQKPGSPPQYLLRYKSDSDKQQ
GSGVPSRFSGSKDASANAGILLISGLQSEDEADYYCMIWHSSAWVFGGGTKLTVLRT

SEQ. ID. No. 36 (<u>IMC-41B12</u> cDNA sequence of light chain cDNA
sequence (Ig kappa))
ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACTGGAGTACATTCACAG
GCTGTGCTGACTCAGCCGTCTTCCCTCTCTGCACCTCCTGGAGCATCAGCCAGTCTCACC
TGCACCTTGCGCAGTGGCTTCAATGTTGATTCCTACAGGATATCCTGGTACCAGCAGAAG
CCAGGGAGTCCTCCCCAGTATCTCCTGAGGTACAAATCAGACTCAGATAAGCAGCAGGGC
TCTGGAGTCCCCAGCCGCTTCTCTGGATCCAAAGATGCTTCGGCCAATGCAGGGATTTTA
CTCATCTCTGGGCTCCAGTCTGAGGATGAGGCTGACTATTACTGTATGATTTGGCACAGC
AGCGCTTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTACGTACGGTGGCTGCACCA
TCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTG
TGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCC
CTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTAC
AGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCC
TGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAG
TGTTAG

SEQ ID. No. 37 (Amino acid sequence of kappa Light Chain of
<u>IMC-41B12</u>)
QAVLTQPSSLSAPPGASASLTC<u>TLRSGFNVDSYRI</u>SWYQQKPGSPPQYLL<u>RYKSDSDK</u>QQ
GSGVPSRFSGSKDASANAGILLISGLQSEDEADYYC<u>MIWHSSAWV</u>FGGGTKLTVLRTVAA
PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

FIGURE 2 (Cont'd)

SEQ. ID. No. 38 ((IMC-41B12 Light chain cDNA sequence (Ig lambda))
ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACTGGAGTACATTCACAG
GCTGTGCTGACTCAGCCGTCTTCCCTCTCTGCACCTCCTGGAGCATCAGCCAGTCTCACC
TGCACCTTGCGCAGTGGCTTCAATGTTGATTCCTACAGGATATCCTGGTACCAGCAGAAG
CCAGGGAGTCCTCCCCAGTATCTCCTGAGGTACAAATCAGACTCAGATAAGCAGCAGGGC
TCTGGAGTCCCCAGCCGCTTCTCTGGATCCAAAGATGCTTCGGCCAATGCAGGGATTTTA
CTCATCTCTGGGCTCCAGTCTGAGGATGAGGCTGACTATTACTGTATGATTTGGCACAGC
AGCGCTTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAAGTCAGCCCAAGGCTGCC
CCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTG
GTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGC
AGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTAC
GCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGC
TGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTGCAGAATGCTCT
TGA

SEQ ID. No. 39 (Amino acid sequence of lambda Light Chain of IMC-41B12)
<u>QAVLTQPSSLSAPPGASASLTCTLRSGFNVDSYRISWYQQKPGSPPQYLLRYKSDSDKQQ
GSGVPSRFSGSKDASANAGILLISGLQSEDEADYYCMIWHSSAWVFGGGTKLTVLSQPKA</u>
APSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNK
YAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPAECS

SEQ ID. No. 40 (Kappa or Lambda Light Chain variable amino acid sequence of IMC-41B12)

QAVLTQPSSLSAPPGASASLTCTLRSGFNVDSYRISWYQQKPGSPPQYLLRYKSDSDKQQ
GSGVPSRFSGSKDASANAGILLISGLQSEDEADYYCMIWHSSAWVFGGGTKLTVL

SEQ ID. No. 41 (IMC-41A2 Human heavy chain variable domain amino acid sequence (subgroup III))
EVQLVQSGGGLVKPGGSLRLSCAASGFTFS<u>SYAMH</u>WVRQAPGKGLEWVA<u>VISYDGSNKYY
ADSVKG</u>RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR<u>FSGWPNNYYYYGMDV</u>WGQGTTV
TVSS

SEQ ID. No. 42 (IMC-41A2 Human kappa light chain variable domain amino acid sequence (subgroup II))
DVVMTQSPLSLPVTPGEPASISC<u>RSSQSLLHSNGYNYLD</u>WYLQKPGQSPQLLIY<u>LGSNRA</u>
SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC<u>MQALQTPRT</u>FGQGTKVEIK

SEQ ID. No. 43 (CDR1 cDNA sequence of heavy chain of IMC-41A2)
AGCTATGCTATGCAC

SEQ ID. No. 44 (CDR1 amino acid sequence of heavy chain of IMC-41A2)
SYAMH

FIGURE 2 (Cont'd)

SEQ ID. No. 45 (CDR2 cDNA sequence of heavy chain of IMC-41A2)
GTTATATCATATGATGGAAGTAATAAATACTACGCAGACTCCGTGAAGGGC

SEQ ID. No. 46 (CDR2 amino acid sequence of heavy chain of IMC-41A2)
VISYDGSNKYYADSVKG

SEQ ID. No. 47 (CDR3 cDNA sequence of heavy chain of IMC-41A2)
TTCAGTGGCTGGCCCAACAACTACTACTACTACGGTATGGACGTC

SEQ ID. No. 48 (CDR3 amino acid sequence of heavy chain of IMC-41A2)
FSGWPNNYYYYGMDV

SEQ ID. No. 49 (CDR1 cDNA sequence of light chain of IMC-41A2)
AGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGAT

SEQ ID. No. 50 (CDR1 amino acid sequence of light chain of IMC-41A2)
RSSQSLLHSNGYNYLD

SEQ ID. No. 51 (CDR2 cDNA sequence of light chain of IMC-41A2)
TTGGGTTCTAATCGGGCCTCC

SEQ ID. No. 52 (CDR2 amino acid sequence of light chain of IMC-41A2)
LGSNRAS

SEQ ID. No. 53 (CDR3 cDNA sequence of light chain of IMC-41A2)
ATGCAAGCTCTACAAACTCCTCGGACG

SEQ ID. No. 54 (CDR3 amino acid sequence of light chain of IMC-41A2)
MQALQTPRT

SEQ ID. No. 55 (cDNA Sequence of IMC-41A2 Heavy chain)

GAGGTCCAGCTGGTGCAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTC
TCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCT
CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTAC
GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT
CTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGGTTCAGT

FIGURE 2 (Cont'd)

GGCTGGCCCAACAACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTC
ACCGTCTCAAGC

SEQ ID. No. 56 (Complete IMC-41A2 heavy chain amino acid sequence) (the
heavy chain amino acid sequence is identical to the 41A10 heavy chain)

EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARFSGWPNNYYYYGMDVWGQGTTV
TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV
LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP
SREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID. No. 57 (41A2 Light chain cDNA sequence)

GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCC
ATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGG
TACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCC
TCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATC
AGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCT
CGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA

SEQ ID. No. 58 (Complete IMC-41A2 light chain kappa amino acid sequence)

DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRA
SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPRTFGQGTKVEIKRTVAAPSV
FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL
SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SEQ ID. No. 59 (Human RON Coding Sequence)

Atggagctcctcccgccgctgcctcagtccttctgttgctgctgctgttgcctgccaagcccgcggcgggcgaggactggcagt
gcccgcgcacccctacgcggcctctcgcgactttgacgtgaagtacgtggtgcccagcttctccgccggaggcctggtacagg
ccatggtgacctacgagggcgacagaaatgagagtgctgtgtttgtagccatacgcaatcgcctgcatgtgcttgggcctgacctg
aagtctgtccagagcctggccacgggccctgctggagaccctggctgccagacgtgtgcagcctgtggcccaggaccccacgg
ccctcccggtgacacagacacaaaggtgctggtgctggatcccgcgctgcctgcgctggtcagttgtggctccagcctgcaggg
ccgctgcttcctgcatgacctagagccccaagggacagccgtgcatctggcagcgccagcctgcctcttctcagcccaccataac
cggcccgatgactgccccgactgtgtggccagcccattgggcacccgtgtaactgtggttgagcaaggccaggcctcctatttcta
cgtggcatcctcactggacgcagccgtggctggcagcttcagcccacgctcagtgtctatcaggcgtctcaaggctgacgcctcg
ggattcgcaccgggctttgtggcgttgtcagtgctgcccaagcatcttgtctcctacagtattgaatacgtgcacagcttccacacgg
gagccttcgtatacttcctgactgtacagccggccagcgtgacagatgatcctagtgccctgcacacacgcctggcacggcttagc
gccactgagccagagttgggtgactatcgggagctggtcctcgactgcagatttgctccaaaacgcaggcgccggggggcccc
agaaggcggacagccctaccctgtgctgcaggtggcccactccgctccagtgggtgcccaacttgccactgagctgagcatcgc
cgagggccaggaagtactatttggggtctttgtgactggcaaggatggtggtcctggcgtgggccccaactctgtcgtctgtgcctt
ccccattgacctgctggacacactaattgatgagggtgtggagcgctgttgtgaatccccagtccatccaggcctccggcgaggc

FIGURE 2 (Cont'd)

ctcgacttcttccagtcgcccagttttttgccccaacccgcctggcctggaagccctcagccccaacaccagctgccgccacttccc
tctgctggtcagtagcagcttctcacgtgtggacctattcaatgggctgttgggaccagtacaggtcactgcattgtatgtgacacgc
cttgacaacgtcacagtggcacacatgggcacaatggatgggcgtatcctgcaggtggagctggtcaggtcactaaactacttgct
gtatgtgtccaacttctcactgggtgacagtgggcagcccgtgcagcgggatgtcagtcgtcttggggaccacctactctttgcctc
tggggaccaggttttccaggtacctatccgaggccctggctgccgccacttcctgacctgtgggcgttgcctaagggcatggcatt
tcatgggctgtggctggtgtgggaacatgtgcggccagcagaaggagtgtcctggctcctggcaacaggaccactgcccaccta
agcttactgagttccaccccccacagtggacctctaaggggcagtacaaggctgaccctgtgtggctccaacttctaccttcacccctt
ctggtctggtgcctgagggaacccatcaggtcactgtgggccaaagtccctgccggccactgcccaaggacagctcaaaactca
gaccagtgccccggaaagactttgtagaggagtttgagtgtgaactggagcccttgggcacccaggcagtgggggcctaccaac
gtcagcctcaccgtgactaacatgccaccgggcaagcacttccgggtagacggcacctccgtgctgagaggcttctctttcatgg
agccagtgctgatagcagtgcaacccctctttggcccacgggcaggaggcacctgtctcactcttgaaggccagagtctgtctgta
ggcaccagccgggctgtgctggtcaatgggactgagtgtctgctagcacgggtcagtgaggggcagcttttatgtgccacaccc
cctgggggccacggtggccagtgtccccccttagcctgcaggtggggggtgcccaggtacctggttcctggaccttccagtacaga
gaagaccctgtcgtgctaagcatcagccccaactgtggctacatcaactcccacatcaccatctgtggccagcatctaacttcagc
atggcacttagtgctgtcattccatgacgggcttagggcagtggaaagcaggtgtgagaggcagcttccagagcagcagctgtg
ccgccttcctgaatatgtggtccgagacccccagggatgggtggcagggaatctgagtgcccgaggggatggagctgctggctt
tacactgcctggctttcgcttcctaccccccaccccatccacccagtgccaacctagttccactgaagcctgaggagcatgccattaa
gtttgagtatattgggctgggcgctgtggctgactgtgtgggtatcaacgtgaccgtgggtggtgagagctgccagcacgagttcc
gggggggacatggttgtctgccccctgcccccatccctgcagcttggccaggatggtgcccattgcaggtctgcgtagatggtga
atgtcatatcctgggtagagtggtgcggccagggccagatgggggtcccacagagcacgctccttggtatcctgctgcctttgctgc
tgcttgtggctgcactggcgactgcactggtcttcagctactggtggcggaggaagcagctagttcttcctcccaacctgaatgacc
tggcatccctggaccagactgctggagccacacccctgcctattctgtactcgggctctgactacagaagtggccttgcactccct
gccattgatggtctggattccaccacttgtgtccatggagcatccttctccgatagtgaagatgaatcctgtgtgccactgctgcgga
aagagtccatccagctaagggacctggactctgcgctcttggctgaggtcaaggatgtgctgattccccatgagcgggtggtcac
ccacagtgaccgagtcattggcaaaggccactttggagttgtctaccacggagaatacatagaccaggcccagaatcgaatccaa
tgtgccatcaagtcactaagtcgcatcacagagatgcagcaggtggaggccttcctgcgagagggggctgctcatgcgtggcctg
aaccacccgaatgtgctggctctcattggtatcatgttgccacctgagggcctgccccatgtgctgctgccctatatgtgccacggt
gacctgctccagttcatccgctcacctcagcggaaccccaccgtgaaggacctcatcagctttggcctgcaggtagcccgcggca
tggagtacctggcagagcagaagtttgtgcacagggacctggctgcgcggaactgcatgctggacgagtcattcacagtcaagg
tggctgactttggtttggcccgcgacatcctggacagggagtactatagtgttcaacagcatcgccacgctcgcctacctgtgaagt
ggatggcgctggagagcctgcagacctatagatttaccaccaagtctgatgtgtggtcatttggtgtgctgctgtgggaactgctga
cacggggtgccccaccataccgccacattgacccttttgaccttacccacttcctggcccagggtcggcgcctgccccagcctga
gtattgccctgattctctgtaccaagtgatgcagcaatgctgggaggcagacccagcagtgcgacccacttcagagtactagtgg
gggaggtggagcagatagtgtctgcactgcttggggaccattatgtgcagctgccagcaacctacatgaacttgggccccagca
cctcgcatgagatgaatgtgcgtccagaacagccgcagttctcacccatgccagggaatgtacgccggccccggccactctcag
agcctcctcggcccacttga

SEQ ID. No. 60 (Human Ron Amino Acid Sequence)

MELLPPLPQSFLLLLLLPAKPAAGEDWQCPRTPYAASRDFDVKYVVPSFSAGGLVQAMVT
YEGDRNESAVFVAIRNRLHVLGPDLKSVQSLATGPAGDPGCQTCAACGPGPHGPPGDTDT
KVLVLDPALPALVSCGSSLQGRCFLHDLEPQGTAVHLAAPACLFSAHHNRPDDCPDCVAS
PLGTRVTVVEQGQASYFYVASSLDAAVAGSFSPRSVSIRRLKADASGFAPGFVALSVLPK
HLVSYSIEYVHSFHTGAFVYFLTVQPASVTDDPSALHTRLARLSATEPELGDYRELVLDC
RFAPKRRRRGAPEGGQPYPVLQVAHSAPVGAQLATELSIAEGQEVLFGVFVTGKDGGPGV
GPNSVVCAFPIDLLDTLIDEGVERCCESPVHPGLRRGLDFFQSPSFCPNPPGLEALSPNT
SCRHFPLLVSSSFSRVDLFNGLLGPVQVTALYVTRLDNVTVAHMGTMDGRILQVELVRSL

FIGURE 2 (Cont'd)

```
NYLLYVSNFSLGDSGQPVQRDVSRLGDHLLFASGDQVFQVPIRGPGCRHFLTCGRCLRAW
HFMGCGWCGNMCGQQKECPGSWQQDHCPPKLTEFHPHSGPLRGSTRLTLCGSNFYLHPSG
LVPEGTHQVTVGQSPCRPLPKDSSKLRPVPRKDFVEEFECELEPLGTQAVGPTNVSLTVT
NMPPGKHFRVDGTSVLRGFSFMEPVLIAVQPLFGPRAGGTCLTLEGQSLSVGTSRAVLVN
GTECLLARVSEGQLLCATPPGATVASVPLSLQVGGAQVPGSWTFQYREDPVVLSISPNCG
YINSHITICGQHLTSAWHLVLSFHDGLRAVESRCERQLPEQQLCRLPEYVVRDPQGWVAG
NLSARGDGAAGFTLPGFRFLPPPHPPSANLVPLKPEEHAIKFEYIGLGAVADCVGINVTV
GGESCQHEFRGDMVVCPLPPSLQLGQDGAPLQVCVDGECHILGRVVRPGPDGVPQSTLLG
ILLPLLLLVAALATALVFSYWWRRKQLVLPPNLNDLASLDQTAGATPLPILYSGSDYRSG
LALPAIDGLDSTTCVHGASFSDSEDESCVPLLRKESIQLRDLDSALLAEVKDVLIPHERV
VTHSDRVIGKGHFGVVYHGEYIDQAQNRIQCAIKSLSRITEMQQVEAFLREGLLMRGLNH
PNVLALIGIMLPPEGLPHVLLPYMCHGDLLQFIRSPQRNPTVKDLISFGLQVARGMEYLA
EQKFVHRDLAARNCMLDESFTVKVADFGLARDILDREYYSVQQHRHARLPVKWMALESLQ
TYRFTTKSDVWSFGVLLWELLTRGAPPYRHIDPFDLTHFLAQGRRLPQPEYCPDSLYQVM
QQCWEADPAVRPTFRVLVGEVEQIVSALLGDHYVQLPATYMNLGPSTSHEMNVRPEQPQF
SPMPGNVRRPRPLSEPPRPT
```

Figure 3

MSP-Induced Phosphorylation of MAPK and AKT Is Inhibited By 41A10

Procedure: - serum starve cells O/N
- incubate without (1) or with (2,3,4) 10 nM MSP (15 min, 37C) in the presence of 100 nM 41A10 (3) or 100 nM 42E12 (4)

SeqListing.txt
SEQUENCE LISTING

<110> IMCLONE SYSTEMS INCORPORATED

<120> INHIBITION OF MACROPHAGE-STIMULATING PROTEIN RECEPTOR
      (RON)

<130> 11245/53876

<140> To Be Assigned
<141> Herewith

<150> 60/571,648
<151> 2004-05-13

<160> 60

<170> PatentIn Ver. 3.3

<210> 1
<211> 15
<212> DNA
<213> Homo sapiens

<400> 1
agctatgcta tgcac   15

<210> 2
<211> 5
<212> PRT
<213> Homo sapiens

<400> 2
Ser Tyr Ala Met His
 1   5

<210> 3
<211> 51
<212> DNA
<213> Homo sapiens

<400> 3
gttatatcat atgatggaag taataaatac tacgcagact ccgtgaaggg c   51

<210> 4
<211> 17
<212> PRT
<213> Homo sapiens

<400> 4
Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
 1   5   10   15

Gly

<210> 5
<211> 45
<212> DNA

                         Page 1

SeqListing.txt

<213> Homo sapiens

<400> 5
ttcagtggct ggcccaacaa ctactactac tacggtatgg acgtc   45

<210> 6
<211> 15
<212> PRT
<213> Homo sapiens

<400> 6
Phe Ser Gly Trp Pro Asn Asn Tyr Tyr Tyr Tyr Gly Met Asp Val
 1   5   10   15

<210> 7
<211> 124
<212> PRT
<213> Homo sapiens

<400> 7
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1   5   10   15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
                20   25   30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35   40   45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
    50   55   60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65   70   75   80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

Ala Arg Phe Ser Gly Trp Pro Asn Asn Tyr Tyr Tyr Tyr Gly Met Asp
                100   105   110

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
                115   120

<210> 8
<211> 1422
<212> DNA
<213> Homo sapiens

<400> 8
atgggatggt catgtatcat ccttttttcta gtagcaactg caactggagt acattcagag 60
gtccagctgg tgcagtctgg gggaggcttg gtcaagcctg agggtccct gagactctcc 120
tgtgcagcct ctggattcac cttcagtagc tatgctatgc actgggtccg ccaggctcca 180
ggcaaggggc tggagtgggt ggcagttata tcatatgatg gaagtaataa atactacgca 240
gactccgtga agggccgatt caccatctcc agagacaatt ccaagaacac gctgtatctg 300
caaatgaaca gcctgagagc tgaggacacg gctgtgtatt actgtgcgag gttcagtggc 360
tggcccaaca actactacta ctacggtatg gacgtctggg gccaagggac cacggtcacc 420
gtctcaagcg ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc 480
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg 540
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta 600

Page 2

2/25

SeqListing.txt

```
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc 660
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa 720
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc 780
ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc 840
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag 900
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag 960
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg 1020
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa 1080
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc 1140
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc 1200
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg 1260
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag 1320
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac 1380
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga                     1422
```

<210> 9
<211> 454
<212> PRT
<213> Homo sapiens

<400> 9

```
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1               5                  10                  15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
            20                  25                  30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
    50                  55                  60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Ala Arg Phe Ser Gly Trp Pro Asn Asn Tyr Tyr Tyr Gly Met Asp
            100                 105                 110

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys
        115                 120                 125

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
    130                 135                 140

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
145                 150                 155                 160

Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
                165                 170                 175

Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
            180                 185                 190

Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
        195                 200                 205

Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
    210                 215                 220
```

Page 3

SeqListing.txt

```
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
225                 230             235             240

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
            245             250             255

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
            260             265             270

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
        275             280             285

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
    290             295             300

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
305             310             315             320

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
            325             330             335

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
            340             345             350

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
        355             360             365

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
    370             375             380

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
385             390             395             400

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
            405             410             415

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
            420             425             430

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
            435             440             445

Ser Leu Ser Pro Gly Lys
            450
```

```
<210>  10
<211>  48
<212>  DNA
<213>  Homo sapiens

<400>  10
aggtctagtc agagcctcct gcatagtaat ggattcaact atgtggat              48


<210>  11
<211>  16
<212>  PRT
<213>  Homo sapiens

<400>  11
Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Phe Asn Tyr Val Asp
```

Page 4

1   5   10   15

```
<210> 12
<211> 21
<212> DNA
<213> Homo sapiens

<400> 12
ttcggttctt atcgggcctc c                                               21


<210> 13
<211> 7
<212> PRT
<213> Homo sapiens

<400> 13
Phe Gly Ser Tyr Arg Ala Ser
 1               5


<210> 14
<211> 30
<212> DNA
<213> Homo sapiens

<400> 14
atgcaagctc tgcaaactcc tccctggacg                                     30


<210> 15
<211> 10
<212> PRT
<213> Homo sapiens

<400> 15
Met Gln Ala Leu Gln Thr Pro Pro Trp Thr
 1               5               10


<210> 16
<211> 113
<212> PRT
<213> Homo sapiens

<400> 16
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1               5                   10                      15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
            20                  25                  30

Asn Gly Phe Asn Tyr Val Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35                  40                  45

Pro His Leu Leu Ile Tyr Phe Gly Ser Tyr Arg Ala Ser Gly Val Pro
    50                  55                  60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
```

Page 5

SeqListing.txt

```
                    85                    90                    95
Leu Gln Thr Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
                100                   105                   110

Arg


<210> 17
<211> 720
<212> DNA
<213> Homo sapiens

<400> 17
atgggatggt catgtatcat ccttttttcta gtagcaactg caactggagt acattcagat 60
gttgtgatga ctcagtctcc actctccctg cccgtcaccc ctggagagcc ggcctccatc 120
tcctgcaggt ctagtcagag cctcctgcat agtaatggat caactatgt ggattggtac 180
ctgcagaagc cagggcagtc tccacacctc ttgatctatt tcggttctta tcgggcctcc 240
ggggtccctg acaggttcag tggcagtgga tcaggcacag attttacact gaaaatcagc 300
agagtggagg ctgaggatgt tggggtttat tactgcatgc aagctctgca aactcctccc 360
tggacgttcg gccaagggac caaggtggaa atcagacgta cggtggctgc accatctgtc 420
ttcatcttcc cgccatctga tgagcagttg aaatctggaa ctgcctctgt tgtgtgcctg 480
ctgaataact ctatcccag agaggccaaa gtacagtgga aggtggataa cgccctccaa 540
tcgggtaact cccaggagag tgtcacagag caggacagca aggacagcac ctacagcctc 600
agcagcaccc tgacgctgag caaagcagac tacgagaaac acaaagtcta cgcctgcgaa 660
gtcacccatc agggcctgag ctcgcccgtc acaaagagct tcaacagggg agagtgttag 720


<210> 18
<211> 220
<212> PRT
<213> Homo sapiens

<400> 18
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1               5                   10                  15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
                20                  25                  30

Asn Gly Phe Asn Tyr Val Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
            35                  40                  45

Pro His Leu Leu Ile Tyr Phe Gly Ser Tyr Arg Ala Ser Gly Val Pro
        50                  55                  60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
                85                  90                  95

Leu Gln Thr Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
                100                 105                 110

Arg Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
            115                 120                 125

Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
        130                 135                 140

Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
```

Page 6

SeqListing.txt
145   150   155   160

Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
                165   170   175

Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
                180   185   190

Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
            195   200   205

Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
    210   215   220

<210> 19
<211> 15
<212> DNA
<213> Homo sapiens

<400> 19
agtcactact ggagt   15

<210> 20
<211> 5
<212> PRT
<213> Homo sapiens

<400> 20
Ser His Tyr Trp Ser
  1   5

<210> 21
<211> 48
<212> DNA
<213> Homo sapiens

<400> 21
tacatctatt acagtgggag caccaactac aacccctccc tcaagagt   48

<210> 22
<211> 16
<212> PRT
<213> Homo sapiens

<400> 22
Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
  1   5   10   15

<210> 23
<211> 57
<212> DNA
<213> Homo sapiens

<400> 23
attcccaact actatgatag aagtggttat tatcccggtt actggtactt cgatctc   57

Page 7

SeqListing.txt

```
<210> 24
<211> 19
<212> PRT
<213> Homo sapiens

<400> 24
Ile Pro Asn Tyr Tyr Asp Arg Ser Gly Tyr Tyr Pro Gly Tyr Trp Tyr
1               5                   10                  15

Phe Asp Leu


<210> 25
<211> 127
<212> PRT
<213> Homo sapiens

<400> 25
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15

Ile Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser His
                20                  25                  30

Tyr Trp Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
            35                  40                  45

Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
    50                  55                  60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65                  70                  75                  80

Asn Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
                85                  90                  95

Arg Ile Pro Asn Tyr Tyr Asp Arg Ser Gly Tyr Tyr Pro Gly Tyr Trp
            100                 105                 110

Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser
            115                 120                 125


<210> 26
<211> 1431
<212> DNA
<213> Homo sapiens

<400> 26
atgggatggt catgtatcat ccttttttcta gtagcaactg caactggagt acattcacag 60
gtgcagctgc aggagtccgg cccaggactg gtgaagcctt cggagatcct gtccctcacc 120
tgcactgtct ctggtggctc catcagtagt cactactgga gttgggtccg gcagccccca 180
gggaagggac tggagtggat tgggtacatc tattacagtg ggagcaccaa ctacaacccc 240
tccctcaaga gtcgagtcac catatcagta gacacgtcca agaaccagtt ctccctgaac 300
ctgagctctg tgaccgctgc ggacacggcc gtgtattatt gtgcgagaat tcccaactac 360
tatgatagaa gtggttatta tcccggttac tggtacttcg atctctgggg ccgtggcacc 420
ctggtcaccg tctcaagcgc tagcaccaag ggcccatcgg tcttcccccct ggcaccctcc 480
tccaagagca cctctggggg cacagcggcc ctgggctgcc tggtcaagga ctacttcccc 540
gaaccggtga cggtgtcgtg gaactcaggc gccctgacca gcggcgtgca caccttcccg 600
gctgtcctac agtcctcagg actctactcc ctcagcagcg tggtgaccgt gccctccagc 660
agcttgggca cccagaccta catctgcaac gtgaatcaca gcccagcaa caccaaggtg 720
gacaagaaag ttgagcccaa atcttgtgac aaaactcaca catgcccacc gtgcccagca 780
```
                              Page 8

SeqListing.txt

```
cctgaactcc tggggggacc gtcagtcttc ctcttccccc caaaacccaa ggacacccts  840
atgatctccc ggaccccctga ggtcacatgc gtggtggtgg acgtgagcca cgaagaccct  900
gaggtcaagt tcaactggta cgtggacggc gtggaggtgc ataatgccaa gacaaagccg  960
cggggaggagc agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt cctgcaccag 1020
gactggctga atggcaagga gtacaagtgc aaggtctcca caaagcccct cccagccccc 1080
atcgagaaaa ccatctccaa agccaaaggg cagccccgag aaccacaggt gtacaccctg 1140
cccccatccc gggaggagat gaccaagaac caggtcagcc tgacctgcct ggtcaaaggc 1200
ttctatccca gcgacatcgc cgtggagtgg gagagcaatg ggcagccgga gaacaactac 1260
aagaccacgc ctcccgtgct ggactccgac ggctccttct tcctctatag caagctcacc 1320
gtggacaaga gcaggtggca gcaggggaac gtcttctcat gctccgtgat gcatgaggct 1380
ctgcacaacc actacacgca gaagagcctc tccctgtccc cgggtaaatg a           1431
```

<210> 27
<211> 457
<212> PRT
<213> Homo sapiens

<400> 27

```
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1               5                  10                  15

Ile Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser His
            20                  25                  30

Tyr Trp Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
        35                  40                  45

Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
    50                  55                  60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65                  70                  75                  80

Asn Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
                85                  90                  95

Arg Ile Pro Asn Tyr Tyr Asp Arg Ser Gly Tyr Tyr Pro Gly Tyr Trp
            100                 105                 110

Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala
        115                 120                 125

Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
    130                 135                 140

Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
145                 150                 155                 160

Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
                165                 170                 175

Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
            180                 185                 190

Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
        195                 200                 205

Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
    210                 215                 220

Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
225                 230                 235                 240
```

Page 9

SeqListing.txt

```
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
                245               250               255

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
            260               265               270

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
        275               280               285

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
    290               295               300

Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
305               310               315               320

Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
            325               330               335

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
            340               345               350

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
        355               360               365

Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
    370               375               380

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
385               390               395               400

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
            405               410               415

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
            420               425               430

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
            435               440               445

Lys Ser Leu Ser Leu Ser Pro Gly Lys
    450               455
```

<210> 28

<400> 28
000

<210> 29
<211> 14
<212> PRT
<213> Homo sapiens

<400> 29
```
Thr Leu Arg Ser Gly Phe Asn Val Asp Ser Tyr Arg Ile Ser
  1               5                 10
```

<210> 30
<211> 42
<212> DNA

SeqListing.txt

```
<213> Homo sapiens

<400> 30
accttgcgca gtggcttcaa tgttgattcc tacaggatat cc                    42


<210> 31
<211> 21
<212> DNA
<213> Homo sapiens

<400> 31
tacaaatcag actcagataa g                                           21


<210> 32
<211> 7
<212> PRT
<213> Homo sapiens

<400> 32
Tyr Lys Ser Asp Ser Asp Lys
 1               5


<210> 33
<211> 27
<212> DNA
<213> Homo sapiens

<400> 33
atgatttggc acagcagcgc ttgggtg                                     27


<210> 34
<211> 9
<212> PRT
<213> Homo sapiens

<400> 34
Met Ile Trp His Ser Ser Ala Trp Val
 1               5


<210> 35
<211> 117
<212> PRT
<213> Homo sapiens

<400> 35
Gln Ala Val Leu Thr Gln Pro Ser Ser Leu Ser Ala Pro Pro Gly Ala
 1               5                   10                  15

Ser Ala Ser Leu Thr Cys Thr Leu Arg Ser Gly Phe Asn Val Asp Ser
                20                  25                  30

Tyr Arg Ile Ser Trp Tyr Gln Gln Lys Pro Gly Ser Pro Pro Gln Tyr
            35                  40                  45

Leu Leu Arg Tyr Lys Ser Asp Ser Asp Lys Gln Gln Gly Ser Gly Val
        50                  55                  60

Pro Ser Arg Phe Ser Gly Ser Lys Asp Ala Ser Ala Asn Ala Gly Ile
                            Page 11
```

SeqListing.txt

```
     65                        70                        75                        80
```

Leu Leu Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys
                    85   90   95

Met Ile Trp His Ser Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu
                100   105   110

Thr Val Leu Arg Thr
            115

<210> 36
<211> 726
<212> DNA
<213> Homo sapiens

<400> 36
```
atgggatggt catgtatcat ccttttttcta gtagcaactg caactggagt acattcacag 60
gctgtgctga ctcagccgtc ttccctctct gcacctcctg gagcatcagc cagtctcacc 120
tgcaccttgc gcagtggctt caatgttgat tcctacagga tatcctggta ccagcagaag 180
ccagggagtc ctccccagta tctcctgagg tacaaatcag actcagataa gcagcagggc 240
tctggagtcc ccagccgctt ctctggatcc aaagatgctt cggccaatgc agggattttta 300
ctcatctctg ggctccagtc tgaggatgag gctgactatt actgtatgat ttggcacagc 360
agcgcttggg tgttcggcgg agggaccaag ctgaccgtcc tacgtacggt ggctgcacca 420
tctgtcttca tcttcccgcc atctgatgag cagttgaaat ctggaactgc ctctgttgtg 480
tgcctgctga ataacttcta tcccagagag gccaaagtac agtggaaggt ggataacgcc 540
ctccaatcgg gtaactccca ggagagtgtc acagagcagg acagcaagga cagcacctac 600
agcctcagca gcaccctgac gctgagcaaa gcagactacg agaaacacaa agtctacgcc 660
tgcgaagtca cccatcaggg cctgagctcg cccgtcacaa agagcttcaa caggggagag 720
tgttag                                                           726
```

<210> 37
<211> 222
<212> PRT
<213> Homo sapiens

<400> 37
Gln Ala Val Leu Thr Gln Pro Ser Ser Leu Ser Ala Pro Pro Gly Ala
  1   5   10   15

Ser Ala Ser Leu Thr Cys Thr Leu Arg Ser Gly Phe Asn Val Asp Ser
                20   25   30

Tyr Arg Ile Ser Trp Tyr Gln Gln Lys Pro Gly Ser Pro Pro Gln Tyr
            35   40   45

Leu Leu Arg Tyr Lys Ser Asp Ser Asp Lys Gln Gln Gly Ser Gly Val
        50   55   60

Pro Ser Arg Phe Ser Gly Ser Lys Asp Ala Ser Ala Asn Ala Gly Ile
65   70   75   80

Leu Leu Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys
                    85   90   95

Met Ile Trp His Ser Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu
                100   105   110

Thr Val Leu Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
            115   120   125

Page 12

SeqListing.txt

```
Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
    130             135             140
Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
145             150             155             160
Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
            165             170             175
Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
            180             185             190
Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
            195             200             205
Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
    210             215             220
```

```
<210> 38
<211> 723
<212> DNA
<213> Homo sapiens

<400> 38
atgggatggt catgtatcat ccttttttcta gtagcaactg caactggagt acattcacag 60
gctgtgctga ctcagccgtc ttccctctct gcacctcctg gagcatcagc cagtctcacc 120
tgcaccttgc gcagtggctt caatgttgat tcctacagga tatcctggta ccagcagaag 180
ccagggagtc ctccccagta tctcctgagg tacaaatcag actcagataa gcagcagggc 240
tctggagtcc ccagccgctt ctctggatcc aaagatgctt cggccaatgc agggattta 300
ctcatctctg ggctccagtc tgaggatgag gctgactatt actgtatgat ttggcacagc 360
agcgcttggg tgttcggcgg agggaccaag ctgaccgtcc taagtcagcc caaggctgcc 420
ccctcggtca ctctgttccc gccctcctct gaggagcttc aagccaacaa ggccacactg 480
gtgtgtctca taagtgactt ctacccggga gccgtgacag tggcctggaa ggcagatagc 540
agccccgtca aggcgggagt ggagaccacc acacctccaa acaaagcaa caacaagtac 600
gcggccagca gctatctgag cctgacgcct gagcagtgga agtcccacag aagctacagc 660
tgccaggtca cgcatgaagg gagcaccgtg gagaagacag tggcccctgc agaatgctct 720
tga                                                          723
```

```
<210> 39
<211> 221
<212> PRT
<213> Homo sapiens

<400> 39
Gln Ala Val Leu Thr Gln Pro Ser Ser Leu Ser Ala Pro Pro Gly Ala
  1               5              10              15
Ser Ala Ser Leu Thr Cys Thr Leu Arg Ser Gly Phe Asn Val Asp Ser
            20              25              30
Tyr Arg Ile Ser Trp Tyr Gln Gln Lys Pro Gly Ser Pro Pro Gln Tyr
        35              40              45
Leu Leu Arg Tyr Lys Ser Asp Ser Asp Lys Gln Gln Gly Ser Gly Val
    50              55              60
Pro Ser Arg Phe Ser Gly Ser Lys Asp Ala Ser Ala Asn Ala Gly Ile
65              70              75              80
Leu Leu Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys
                85              90              95
```

Page 13

SeqListing.txt

```
Met Ile Trp His Ser Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu
            100                 105                 110

Thr Val Leu Ser Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro
        115                 120                 125

Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu
        130                 135                 140

Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp
145                 150                 155                 160

Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln
                165                 170                 175

Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu
            180                 185                 190

Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly
        195                 200                 205

Ser Thr Val Glu Lys Thr Val Ala Pro Ala Glu Cys Ser
        210                 215                 220
```

```
<210> 40
<211> 115
<212> PRT
<213> Homo sapiens

<400> 40
Gln Ala Val Leu Thr Gln Pro Ser Ser Leu Ser Ala Pro Pro Gly Ala
  1               5                  10                  15

Ser Ala Ser Leu Thr Cys Thr Leu Arg Ser Gly Phe Asn Val Asp Ser
                20                  25                  30

Tyr Arg Ile Ser Trp Tyr Gln Gln Lys Pro Gly Ser Pro Pro Gln Tyr
            35                  40                  45

Leu Leu Arg Tyr Lys Ser Asp Ser Asp Lys Gln Gln Gly Ser Gly Val
        50                  55                  60

Pro Ser Arg Phe Ser Gly Ser Lys Asp Ala Ser Ala Asn Ala Gly Ile
65                  70                  75                  80

Leu Leu Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys
                85                  90                  95

Met Ile Trp His Ser Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu
            100                 105                 110

Thr Val Leu
        115
```

```
<210> 41
<211> 124
<212> PRT
<213> Homo sapiens

<400> 41
```

SeqListing.txt

```
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1               5                   10                  15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
            20                  25                  30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
    50                  55                  60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                  70                  75                  80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95

Ala Arg Phe Ser Gly Trp Pro Asn Asn Tyr Tyr Tyr Tyr Gly Met Asp
            100                 105                 110

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
            115                 120
```

<210> 42
<211> 112
<212> PRT
<213> Homo sapiens

<400> 42
```
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1               5                   10                  15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
            20                  25                  30

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35                  40                  45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
    50                  55                  60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
                85                  90                  95

Leu Gln Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
            100                 105                 110
```

<210> 43
<211> 15
<212> DNA
<213> Homo sapiens

<400> 43
agctatgcta tgcac   15

Page 15

SeqListing.txt

```
<210> 44
<211> 5
<212> PRT
<213> Homo sapiens

<400> 44
Ser Tyr Ala Met His
 1               5


<210> 45
<211> 51
<212> DNA
<213> Homo sapiens

<400> 45
gttatatcat atgatggaag taataaatac tacgcagact ccgtgaaggg c          51


<210> 46
<211> 17
<212> PRT
<213> Homo sapiens

<400> 46
Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
 1               5                   10                  15

Gly


<210> 47
<211> 45
<212> DNA
<213> Homo sapiens

<400> 47
ttcagtggct ggcccaacaa ctactactac tacggtatgg acgtc                       45


<210> 48
<211> 15
<212> PRT
<213> Homo sapiens

<400> 48
Phe Ser Gly Trp Pro Asn Asn Tyr Tyr Tyr Tyr Gly Met Asp Val
 1               5                   10                  15


<210> 49
<211> 48
<212> DNA
<213> Homo sapiens

<400> 49
aggtctagtc agagcctcct gcatagtaat ggatacaact atttggat                    48


<210> 50
```

Page 16

SeqListing.txt

```
<211> 16
<212> PRT
<213> Homo sapiens

<400> 50
Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp
 1               5                  10                  15


<210> 51
<211> 21
<212> DNA
<213> Homo sapiens

<400> 51
ttgggttcta atcgggcctc c                                                  21


<210> 52
<211> 7
<212> PRT
<213> Homo sapiens

<400> 52
Leu Gly Ser Asn Arg Ala Ser
 1               5


<210> 53
<211> 27
<212> DNA
<213> Homo sapiens

<400> 53
atgcaagctc tacaaactcc tcggacg                                            27


<210> 54
<211> 9
<212> PRT
<213> Homo sapiens

<400> 54
Met Gln Ala Leu Gln Thr Pro Arg Thr
 1               5


<210> 55
<211> 372
<212> DNA
<213> Homo sapiens

<400> 55
gaggtccagc tggtgcagtc tggggaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt agctatgcta tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactac 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gaggttcagt 300
ggctggccca acaactacta ctactacggt atggacgtct ggggccaagg gaccacggtc 360
accgtctcaa gc                                                           372


<210> 56
```

SeqListing.txt

```
<211> 454
<212> PRT
<213> Homo sapiens

<400> 56
```

Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Gly	Gly	Leu	Val	Lys	Pro	Gly	Gly
1				5					10					15	

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
			20				25					30	

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35   40   45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
        50   55   60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65   70   75   80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
                85   90   95

Ala Arg Phe Ser Gly Trp Pro Asn Asn Tyr Tyr Tyr Gly Met Asp
            100   105   110

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys
        115   120   125

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
    130   135   140

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
145   150   155   160

Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
                165   170   175

Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
            180   185   190

Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
        195   200   205

Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
    210   215   220

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
225   230   235   240

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
                245   250   255

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
            260   265   270

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
        275   280   285

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
    290   295   300

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp

SeqListing.txt

```
305                     310                 315                   320
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
            325             330                 335

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
            340             345                 350

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
            355             360                 365

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
    370             375             380

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
385             390                 395                 400

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
            405             410                 415

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
            420             425                 430

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
            435             440                 445

Ser Leu Ser Pro Gly Lys
    450
```

```
<210>  57
<211>  336
<212>  DNA
<213>  Homo sapiens

<400>  57
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 300
cggacgttcg gccaagggac caaggtggaa atcaaa                          336
```

```
<210>  58
<211>  219
<212>  PRT
<213>  Homo sapiens

<400>  58
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
  1             5               10                  15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
            20              25                  30

Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35              40                  45

Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
    50              55                  60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
```

SeqListing.txt

```
     65                        70                        75                        80
```

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
                 85   90   95

Leu Gln Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
                100   105   110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
                115   120   125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
    130   135   140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145   150   155   160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
                165   170   175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
                180   185   190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
                195   200   205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
    210   215

<210> 59
<211> 4203
<212> DNA
<213> Homo sapiens

<400> 59
atggagctcc tcccgccgct gcctcagtcc ttcctgttgc tgctgctgtt gcctgccaag 60
cccgcggcgg gcgaggactg gcagtgcccg cgcacccct acgcggcctc tcgcgacttt 120
gacgtgaagt acgtggtgcc cagcttctcc gccggaggcc tggtacaggc catggtgacc 180
tacgagggcg acagaaatga gagtgctgtg tttgtagcca tacgcaatcg cctgcatgtg 240
cttgggcctg acctgaagtc tgtccagagc ctggccacgg gcccctgctgg agaccctggc 300
tgccagacgt gtgcagcctg tggcccagga ccccacggcc ctccggtga cacagacaca 360
aaggtgctgg tgctggatcc cgcgctgcct gcgctggtca gttgtggctc cagcctgcag 420
ggccgctgct tcctgcatga cctagagccc caagggacag ccgtgcatct ggcagcgcca 480
gcctgcctct tctcagccca ccataaccgg cccgatgact gccccgactg tgtggccagc 540
ccattgggca cccgtgtaac tgtggttgag caaggccagg cctcctattt ctacgtggca 600
tcctcactgg acgcagccgt ggctggcagc ttcagcccac gctcagtgtc tatcaggcgt 660
ctcaaggctg acgcctcggg attcgcaccg ggctttgtgg cgttgtcagt gctgcccaag 720
catcttgtct cctacagtat tgaatacgtg cacagcttcc acacgggagc cttcgtatac 780
ttcctgactg tacagccggc cagcgtgaca gatgatccta gtgccctgca cacacgcctg 840
gcacggctta gcgccactga gccagagttg ggtgactatc gggagctggt cctcgactgc 900
agatttgctc aaaacgcag gcgccgggg gccccagaag cggacagcc ctaccctgtg 960
ctgcaggtgg cccactccgc tccagtgggt gcccaacttg ccactgagct gagcatcgcc 1020
gagggccagg aagtactatt tgggggtcttt gtgactggca aggatggtgg tcctggcgtg 1080
ggccccaact ctgtcgtctg tgccttcccc attgacctgc tggacacact aattgatgag 1140
ggtgtggagc gctgttgtga atccccagtc catccaggcc tccggcgagg cctcgacttc 1200
ttccagtcgc ccagtttttg ccccaacccg cctggcctgg aagccctcag ccccaacacc 1260
agctgccgcc acttccctct gctggtcagt agcagcttct cacgtgtgga cctattcaat 1320
gggctgttgg gaccagtaca ggtcactgca ttgtatgtga cacgccttga caacgtcaca 1380
gtggcacaca tgggcacaat ggatgggcgt atcctgcagg tggagctggt caggtcacta 1440
aactacttgc tgtatgtgtc caacttctca ctgggtgaca gtgggcagcc cgtgcagcgg 1500
gatgtcagtc gtcttgggga ccacctactc tttgcctctg ggaccaggt tttccaggta 1560
cctatccgag ccctggctg ccgccacttc ctgacctgtg ggcgttgcct aagggcatgg 1620
```

SeqListing.txt

```
catttcatgg gctgtggctg gtgtgggaac atgtgcggcc agcagaagga gtgtcctggc 1680
tcctggcaac aggaccactg cccacctaag cttactgagt tccacccca cagtggacct 1740
ctaaggggca gtacaaggct gaccctgtgt ggctccaact tctaccttca cccttctggt 1800
ctggtgcctg agggaaccca tcaggtcact gtgggccaaa gtccctgccg gccactgccc 1860
aaggacagct caaaactcag accagtgccc cggaaagact ttgtagagga gtttgagtgt 1920
gaactggagc ccttgggcac ccaggcagtg gggcctacca acgtcagcct caccgtgact 1980
aacatgccac cgggcaagca cttccgggta gacggcacct ccgtgctgag aggcttctct 2040
ttcatggagc cagtgctgat agcagtgcaa cccctctttg cccacgggc aggaggcacc 2100
tgtctcactc ttgaaggcca gagtctgtct gtaggcacca gccgggctgt gctggtcaat 2160
gggactgagt gtctgctagc acgggtcagt gaggggcagc ttttatgtgc cacacccct 2220
ggggccacgg tggccagtgt ccccttagc ctgcaggtgg ggggtgccca ggtacctggt 2280
tcctggacct tccagtacag agaagaccct gtcgtgctaa gcatcagccc caactgtggc 2340
tacatcaact cccacatcac catctgtggc cagcatctaa cttcagcatg gcacttagtg 2400
ctgtcattcc atgacgggct tagggcagtg gaaagcaggt gtgagaggca gcttccagag 2460
cagcagctgt gccgccttcc tgaatatgtg gtccgagacc cccagggatg ggtggcaggg 2520
aatctgagtg cccgagggga tggagctgct ggctttacac tgcctggctt tcgcttccta 2580
cccccacccc atccacccag tgccaaccta gttccactga agcctgagga gcatgccatt 2640
aagtttgagt atattgggct gggcgctgtg gctgactgtg tgggtatcaa cgtgaccgtg 2700
ggtggtgaga gctgccagca cgagttccgg ggggacatgg ttgtctgccc cctgcccca 2760
tccctgcagc ttggccagga tggtgcccca ttgcaggtct gcgtagatgg tgaatgtcat 2820
atcctgggta gagtggtgcg gccagggcca gatggggtcc cacagagcac gctccttggt 2880
atcctgctgc cttttgctgct gcttgtggct gcactggcga ctgcactggt cttcagctac 2940
tggtggcgga ggaagcagct agttcttcct cccaacctga atgacctggc atccctggac 3000
cagactgctg gagccacacc cctgcctatt ctgtactcgg gctctgacta cagaagtggc 3060
cttgcactcc ctgccattga tggtctggat tccaccactt gtgtccatgg agcatccttc 3120
tccgatagtg aagatgaatc ctgtgtgcca ctgctgcgga aagagtccat ccagctaagg 3180
gacctggact ctgcgctctt ggctgaggtc aaggatgtgc tgattcccca tgagcgggtg 3240
gtcacccaca gtgaccgagt cattggcaaa ggccactttg gagttgtcta ccacggagaa 3300
tacatagacc aggcccagaa tcgaatccaa tgtgccatca gtcactaag tcgcatcaca 3360
gagatgcagc aggtggaggc cttcctgcga gaggggctgc tcatgcgtgg cctgaaccac 3420
ccgaatgtgc tggctctcat tggtatcatg ttgccacctg agggcctgcc ccatgtgctg 3480
ctgccctata tgtgccacgg tgacctgctc cagttcatcc gctcacctca gcggaacccc 3540
accgtgaagg acctcatcag ctttggcctg caggtagccc gcggcatgga gtacctggca 3600
gagcagaagt ttgtgcacag ggacctggct gcgcggaact gcatgctgga cgagtcattc 3660
acagtcaagg tggctgactt tggttttggcc cgcgacatcc tggacaggga gtactatagt 3720
gttcaacagc atcgccacgc tcgcctacct gtgaagtgga tggcgctgga gagcctgcag 3780
acctatagat ttaccaccaa gtctgatgtg tggtcatttg gtgtgctgct gtgggaactg 3840
ctgacacggg gtgccccacc ataccgccac attgacccct ttgaccttac ccacttcctg 3900
gcccagggtc ggcgcctgcc ccagcctgag tattgccctg attctctgta ccaagtgatg 3960
cagcaatgct gggaggcaga cccagcagtg cgacccacct tcagagtact agtgggggag 4020
gtggagcaga tagtgtctgc actgcttggg gaccattatg tgcagctgcc agcaacctac 4080
atgaacttgg ccccagcac ctcgcatgag atgaatgtgc gtccagaaca gccgcagttc 4140
tcacccatgc cagggaatgt acgccggccc cggccactct cagagcctcc tcggcccact 4200
tga                                                                4203
```

<210> 60
<211> 1400
<212> PRT
<213> Homo sapiens

<400> 60

```
Met Glu Leu Leu Pro Pro Leu Pro Gln Ser Phe Leu Leu Leu Leu
  1               5                  10                 15

Leu Pro Ala Lys Pro Ala Ala Gly Glu Asp Trp Gln Cys Pro Arg Thr
             20                  25                 30

Pro Tyr Ala Ala Ser Arg Asp Phe Asp Val Lys Tyr Val Val Pro Ser
         35                  40                 45

Phe Ser Ala Gly Gly Leu Val Gln Ala Met Val Thr Tyr Glu Gly Asp
     50                  55                 60
```

Page 21

SeqListing.txt

```
Arg Asn Glu Ser Ala Val Phe Val Ala Ile Arg Asn Arg Leu His Val
65              70              75              80

Leu Gly Pro Asp Leu Lys Ser Val Gln Ser Leu Ala Thr Gly Pro Ala
            85              90              95

Gly Asp Pro Gly Cys Gln Thr Cys Ala Ala Cys Gly Pro Gly Pro His
            100             105             110

Gly Pro Pro Gly Asp Thr Asp Thr Lys Val Leu Val Leu Asp Pro Ala
        115             120             125

Leu Pro Ala Leu Val Ser Cys Gly Ser Ser Leu Gln Gly Arg Cys Phe
    130             135             140

Leu His Asp Leu Glu Pro Gln Gly Thr Ala Val His Leu Ala Ala Pro
145             150             155             160

Ala Cys Leu Phe Ser Ala His His Asn Arg Pro Asp Asp Cys Pro Asp
            165             170             175

Cys Val Ala Ser Pro Leu Gly Thr Arg Val Thr Val Val Glu Gln Gly
            180             185             190

Gln Ala Ser Tyr Phe Tyr Val Ala Ser Ser Leu Asp Ala Ala Val Ala
    195             200             205

Gly Ser Phe Ser Pro Arg Ser Val Ser Ile Arg Arg Leu Lys Ala Asp
210             215             220

Ala Ser Gly Phe Ala Pro Gly Phe Val Ala Leu Ser Val Leu Pro Lys
225             230             235             240

His Leu Val Ser Tyr Ser Ile Glu Tyr Val His Ser Phe His Thr Gly
            245             250             255

Ala Phe Val Tyr Phe Leu Thr Val Gln Pro Ala Ser Val Thr Asp Asp
            260             265             270

Pro Ser Ala Leu His Thr Arg Leu Ala Arg Leu Ser Ala Thr Glu Pro
    275             280             285

Glu Leu Gly Asp Tyr Arg Glu Leu Val Leu Asp Cys Arg Phe Ala Pro
    290             295             300

Lys Arg Arg Arg Arg Gly Ala Pro Glu Gly Gly Gln Pro Tyr Pro Val
305             310             315             320

Leu Gln Val Ala His Ser Ala Pro Val Gly Ala Gln Leu Ala Thr Glu
            325             330             335

Leu Ser Ile Ala Glu Gly Gln Glu Val Leu Phe Gly Val Phe Val Thr
            340             345             350

Gly Lys Asp Gly Gly Pro Gly Val Gly Pro Asn Ser Val Val Cys Ala
    355             360             365

Phe Pro Ile Asp Leu Leu Asp Thr Leu Ile Asp Glu Gly Val Glu Arg
    370             375             380

Cys Cys Glu Ser Pro Val His Pro Gly Leu Arg Arg Gly Leu Asp Phe
385             390             395             400
```

Page 22

SeqListing.txt

Phe Gln Ser Pro Ser Phe Cys Pro Asn Pro Pro Gly Leu Glu Ala Leu
            405   410   415

Ser Pro Asn Thr Ser Cys Arg His Phe Pro Leu Leu Val Ser Ser Ser
            420   425   430

Phe Ser Arg Val Asp Leu Phe Asn Gly Leu Leu Gly Pro Val Gln Val
        435   440   445

Thr Ala Leu Tyr Val Thr Arg Leu Asp Asn Val Thr Val Ala His Met
    450   455   460

Gly Thr Met Asp Gly Arg Ile Leu Gln Val Glu Leu Val Arg Ser Leu
465   470   475   480

Asn Tyr Leu Leu Tyr Val Ser Asn Phe Ser Leu Gly Asp Ser Gly Gln
                485   490   495

Pro Val Gln Arg Asp Val Ser Arg Leu Gly Asp His Leu Leu Phe Ala
            500   505   510

Ser Gly Asp Gln Val Phe Gln Val Pro Ile Arg Gly Pro Gly Cys Arg
            515   520   525

His Phe Leu Thr Cys Gly Arg Cys Leu Arg Ala Trp His Phe Met Gly
    530   535   540

Cys Gly Trp Cys Gly Asn Met Cys Gly Gln Gln Lys Glu Cys Pro Gly
545   550   555   560

Ser Trp Gln Gln Asp His Cys Pro Pro Lys Leu Thr Glu Phe His Pro
            565   570   575

His Ser Gly Pro Leu Arg Gly Ser Thr Arg Leu Thr Leu Cys Gly Ser
            580   585   590

Asn Phe Tyr Leu His Pro Ser Gly Leu Val Pro Glu Gly Thr His Gln
        595   600   605

Val Thr Val Gly Gln Ser Pro Cys Arg Pro Leu Pro Lys Asp Ser Ser
    610   615   620

Lys Leu Arg Pro Val Pro Arg Lys Asp Phe Val Glu Glu Phe Glu Cys
625   630   635   640

Glu Leu Glu Pro Leu Gly Thr Gln Ala Val Gly Pro Thr Asn Val Ser
            645   650   655

Leu Thr Val Thr Asn Met Pro Pro Gly Lys His Phe Arg Val Asp Gly
            660   665   670

Thr Ser Val Leu Arg Gly Phe Ser Phe Met Glu Pro Val Leu Ile Ala
    675   680   685

Val Gln Pro Leu Phe Gly Pro Arg Ala Gly Gly Thr Cys Leu Thr Leu
    690   695   700

Glu Gly Gln Ser Leu Ser Val Gly Thr Ser Arg Ala Val Leu Val Asn
705   710   715   720

Gly Thr Glu Cys Leu Leu Ala Arg Val Ser Glu Gly Gln Leu Leu Cys
            725   730   735

Page 23

SeqListing.txt

Ala Thr Pro Pro Gly Ala Thr Val Ala Ser Val Pro Leu Ser Leu Gln
            740   745   750

Val Gly Gly Ala Gln Val Pro Gly Ser Trp Thr Phe Gln Tyr Arg Glu
        755   760   765

Asp Pro Val Val Leu Ser Ile Ser Pro Asn Cys Gly Tyr Ile Asn Ser
    770   775   780

His Ile Thr Ile Cys Gly Gln His Leu Thr Ser Ala Trp His Leu Val
785   790   795   800

Leu Ser Phe His Asp Gly Leu Arg Ala Val Glu Ser Arg Cys Glu Arg
            805   810   815

Gln Leu Pro Glu Gln Gln Leu Cys Arg Leu Pro Glu Tyr Val Val Arg
            820   825   830

Asp Pro Gln Gly Trp Val Ala Gly Asn Leu Ser Ala Arg Gly Asp Gly
            835   840   845

Ala Ala Gly Phe Thr Leu Pro Gly Phe Arg Phe Leu Pro Pro Pro His
    850   855   860

Pro Pro Ser Ala Asn Leu Val Pro Leu Lys Pro Glu Glu His Ala Ile
865   870   875   880

Lys Phe Glu Tyr Ile Gly Leu Gly Ala Val Ala Asp Cys Val Gly Ile
            885   890   895

Asn Val Thr Val Gly Gly Glu Ser Cys Gln His Glu Phe Arg Gly Asp
            900   905   910

Met Val Val Cys Pro Leu Pro Pro Ser Leu Gln Leu Gly Gln Asp Gly
            915   920   925

Ala Pro Leu Gln Val Cys Val Asp Gly Glu Cys His Ile Leu Gly Arg
    930   935   940

Val Val Arg Pro Gly Pro Asp Gly Val Pro Gln Ser Thr Leu Leu Gly
945   950   955   960

Ile Leu Leu Pro Leu Leu Leu Val Ala Ala Leu Ala Thr Ala Leu
            965   970   975

Val Phe Ser Tyr Trp Trp Arg Arg Lys Gln Leu Val Leu Pro Pro Asn
            980   985   990

Leu Asn Asp Leu Ala Ser Leu Asp Gln Thr Ala Gly Ala Thr Pro Leu
    995   1000   1005

Pro Ile Leu Tyr Ser Gly Ser Asp Tyr Arg Ser Gly Leu Ala Leu Pro
    1010   1015   1020

Ala Ile Asp Gly Leu Asp Ser Thr Thr Cys Val His Gly Ala Ser Phe
1025   1030   1035   1040

Ser Asp Ser Glu Asp Glu Ser Cys Val Pro Leu Leu Arg Lys Glu Ser
            1045   1050   1055

Ile Gln Leu Arg Asp Leu Asp Ser Ala Leu Leu Ala Glu Val Lys Asp
            1060   1065   1070

Page 24

SeqListing.txt

Val Leu Ile Pro His Glu Arg Val Val Thr His Ser Asp Arg Val Ile
      1075   1080   1085

Gly Lys Gly His Phe Gly Val Val Tyr His Gly Glu Tyr Ile Asp Gln
      1090   1095   1100

Ala Gln Asn Arg Ile Gln Cys Ala Ile Lys Ser Leu Ser Arg Ile Thr
1105   1110   1115   1120

Glu Met Gln Gln Val Glu Ala Phe Leu Arg Glu Gly Leu Leu Met Arg
            1125   1130   1135

Gly Leu Asn His Pro Asn Val Leu Ala Leu Ile Gly Ile Met Leu Pro
            1140   1145   1150

Pro Glu Gly Leu Pro His Val Leu Leu Pro Tyr Met Cys His Gly Asp
      1155   1160   1165

Leu Leu Gln Phe Ile Arg Ser Pro Gln Arg Asn Pro Thr Val Lys Asp
      1170   1175   1180

Leu Ile Ser Phe Gly Leu Gln Val Ala Arg Gly Met Glu Tyr Leu Ala
1185   1190   1195   1200

Glu Gln Lys Phe Val His Arg Asp Leu Ala Ala Arg Asn Cys Met Leu
            1205   1210   1215

Asp Glu Ser Phe Thr Val Lys Val Ala Asp Phe Gly Leu Ala Arg Asp
            1220   1225   1230

Ile Leu Asp Arg Glu Tyr Tyr Ser Val Gln Gln His Arg His Ala Arg
      1235   1240   1245

Leu Pro Val Lys Trp Met Ala Leu Glu Ser Leu Gln Thr Tyr Arg Phe
      1250   1255   1260

Thr Thr Lys Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu Leu
1265   1270   1275   1280

Leu Thr Arg Gly Ala Pro Pro Tyr Arg His Ile Asp Pro Phe Asp Leu
            1285   1290   1295

Thr His Phe Leu Ala Gln Gly Arg Arg Leu Pro Gln Pro Glu Tyr Cys
            1300   1305   1310

Pro Asp Ser Leu Tyr Gln Val Met Gln Gln Cys Trp Glu Ala Asp Pro
      1315   1320   1325

Ala Val Arg Pro Thr Phe Arg Val Leu Val Gly Glu Val Glu Gln Ile
      1330   1335   1340

Val Ser Ala Leu Leu Gly Asp His Tyr Val Gln Leu Pro Ala Thr Tyr
1345   1350   1355   1360

Met Asn Leu Gly Pro Ser Thr Ser His Glu Met Asn Val Arg Pro Glu
            1365   1370   1375

Gln Pro Gln Phe Ser Pro Met Pro Gly Asn Val Arg Arg Pro Arg Pro
            1380   1385   1390

Leu Ser Glu Pro Pro Arg Pro Thr
      1395   1400

                              Page 25